BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474-1486. [PMID: 1681750 DOI: 10.1176/ajp.148.11.1474] [Cited by in Crossref: 1218] [Cited by in F6Publishing: 1015] [Article Influence: 40.6] [Reference Citation Analysis]
Number Citing Articles
1 Sarkanen T, Niemelä V, Landtblom AM, Partinen M. Psychosis in patients with narcolepsy as an adverse effect of sodium oxybate. Front Neurol 2014;5:136. [PMID: 25191304 DOI: 10.3389/fneur.2014.00136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
2 Annafi OS, Aluko OM, Eduviere AT, Omorogbe O, Umukoro S. Probable mechanisms involved in the antipsychotic-like activity of methyl jasmonate in mice. Naunyn Schmiedebergs Arch Pharmacol 2017;390:883-92. [PMID: 28612111 DOI: 10.1007/s00210-017-1386-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, Bogerts B, Braun K, Jankowski Z, Kumaratilake J, Henneberg M, Gos T. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 2014;5:47. [PMID: 24904434 DOI: 10.3389/fpsyt.2014.00047] [Cited by in Crossref: 54] [Cited by in F6Publishing: 93] [Article Influence: 7.7] [Reference Citation Analysis]
4 Abdoli A, Dalimi A, Arbabi M, Ghaffarifar F. Neuropsychiatric manifestations of latent toxoplasmosis on mothers and their offspring. J Matern Fetal Neonatal Med 2014;27:1368-74. [PMID: 24156764 DOI: 10.3109/14767058.2013.858685] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
5 Lambert GW, Ferrier C, Kaye DM, Kalff V, Kelly MJ, Cox HS, Turner AG, Jennings GL, Esler MD. Monoaminergic Neuronal Activity in Subcortical Brain Regions in Essential Hypertension. Blood Pressure 2009;3:55-66. [DOI: 10.3109/08037059409101522] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
6 Lee CS, Yu SH, Kim TH. One-Step Electrochemical Fabrication of Reduced Graphene Oxide/Gold Nanoparticles Nanocomposite-Modified Electrode for Simultaneous Detection of Dopamine, Ascorbic Acid, and Uric Acid. Nanomaterials (Basel) 2017;8:E17. [PMID: 29301209 DOI: 10.3390/nano8010017] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
7 Tuckwell HC, Koziol JA. On the concentration of 5-hydroxyindoleacetic acid in schizophrenia: a meta-analysis. Psychiatry Res 1996;59:239-44. [PMID: 8930029 DOI: 10.1016/0165-1781(95)02741-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
8 Ellenbroek BA, Liégeois JF. JL 13, an atypical antipsychotic: a preclinical review. CNS Drug Rev 2003;9:41-56. [PMID: 12595911 DOI: 10.1111/j.1527-3458.2003.tb00243.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
9 Wang X, Gu Z, Zhong P, Chen G, Feng J, Yan Z. Aberrant regulation of NMDA receptors by dopamine D4 signaling in rats after phencyclidine exposure. Mol Cell Neurosci 2006;31:15-25. [PMID: 16198123 DOI: 10.1016/j.mcn.2005.08.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
10 Colzato LS, Huizinga M, Hommel B. Recreational cocaine polydrug use impairs cognitive flexibility but not working memory. Psychopharmacology (Berl) 2009;207:225-34. [PMID: 19727676 DOI: 10.1007/s00213-009-1650-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
11 Vijayan NN, Bhaskaran S, Koshy LV, Natarajan C, Srinivas L, Nair CM, Allencherry PM, Banerjee M. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. Behav Brain Funct 2007;3:34. [PMID: 17651483 DOI: 10.1186/1744-9081-3-34] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
12 Braver TS, Barch DM, Cohen JD. Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function. Biological Psychiatry 1999;46:312-28. [DOI: 10.1016/s0006-3223(99)00116-x] [Cited by in Crossref: 326] [Cited by in F6Publishing: 105] [Article Influence: 14.8] [Reference Citation Analysis]
13 Girgis RR, Slifstein M, Brucato G, Kegeles LS, Colibazzi T, Lieberman JA, Abi-Dargham A. Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study. Mol Psychiatry 2021;26:2504-13. [PMID: 33154566 DOI: 10.1038/s41380-020-00934-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, Hwang Y, Hwang DR, Abi-Dargham A, Laruelle M. In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 2007;9:117-25. [PMID: 17473957 DOI: 10.1007/s11307-007-0077-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
15 Eisenstein SA, Bogdan R, Chen L, Moerlein SM, Black KJ, Perlmutter JS, Hershey T, Barch DM. Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia. J Psychiatr Res 2017;86:9-17. [PMID: 27886638 DOI: 10.1016/j.jpsychires.2016.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
16 Rangel-Barajas C, Malik M, Mach RH, Luedtke RR. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds. Neuropharmacology 2015;93:179-90. [PMID: 25698528 DOI: 10.1016/j.neuropharm.2014.10.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Javanbakht A. The theory of bowl and bugs: a model for the explanation of the coexistence of psychological and biological etiologies in the psychosis. J Am Acad Psychoanal Dyn Psychiatry 2005;33:363-75. [PMID: 16193549 DOI: 10.1521/jaap.2005.33.2.363] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 De Brabander B, Declerck CH. A possible role of central dopamine metabolism associated with individual differences in locus of control. Personality and Individual Differences 2004;37:735-50. [DOI: 10.1016/j.paid.2003.11.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
19 Fumagalli F, Frasca A, Racagni G, Riva MA. Cognitive Effects of Second-Generation Antipsychotics: Current Insights into Neurochemical Mechanisms. CNS Drugs 2009;23:603-14. [DOI: 10.2165/00023210-200923070-00005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
20 Howes OD, McCutcheon R, Owen MJ, Murray RM. The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. Biol Psychiatry. 2017;81:9-20. [PMID: 27720198 DOI: 10.1016/j.biopsych.2016.07.014] [Cited by in Crossref: 256] [Cited by in F6Publishing: 147] [Article Influence: 51.2] [Reference Citation Analysis]
21 Ishii D, Matsuzawa D, Kanahara N, Matsuda S, Sutoh C, Ohtsuka H, Nakazawa K, Kohno M, Hashimoto K, Iyo M, Shimizu E. Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. Neurosci Lett 2010;471:53-7. [PMID: 20083164 DOI: 10.1016/j.neulet.2010.01.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
22 Alttoa A, Harro J. Effect of CCK1 and CCK2 receptor blockade on amphetamine-stimulated exploratory behavior and sensitization to amphetamine. Eur Neuropsychopharmacol 2004;14:324-31. [PMID: 15163443 DOI: 10.1016/j.euroneuro.2003.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
23 Goff DC. Drug development in schizophrenia: are glutamatergic targets still worth aiming at? Curr Opin Psychiatry 2015;28:207-15. [PMID: 25710242 DOI: 10.1097/YCO.0000000000000152] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
24 Hui CL, Wong GH, Tang JY, Chang W, Chan SK, Lee EH, Lam MM, Chiu CP, Law C, Chung DW, Tso S, Pang EP, Chan K, Wong Y, Mo FY, Chan KP, Hung S, Honer WG, Chen EY. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophrenia Research 2013;150:297-302. [DOI: 10.1016/j.schres.2013.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
25 Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry. 2005;10:27-39. [PMID: 15340352 DOI: 10.1038/sj.mp.4001563] [Cited by in Crossref: 165] [Cited by in F6Publishing: 146] [Article Influence: 10.3] [Reference Citation Analysis]
26 Wyss C, Hitz K, Hengartner MP, Theodoridou A, Obermann C, Uhl I, Roser P, Grünblatt E, Seifritz E, Juckel G, Kawohl W. The loudness dependence of auditory evoked potentials (LDAEP) as an indicator of serotonergic dysfunction in patients with predominant schizophrenic negative symptoms. PLoS One 2013;8:e68650. [PMID: 23874705 DOI: 10.1371/journal.pone.0068650] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
27 Lee BJ, Lee JG, Kim YH. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol 2007;21:421-7. [PMID: 17092979 DOI: 10.1177/0269881106070996] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
28 Bali A, Reddy ACDK. Synthesis and evaluation of meta substituted 1-(aryloxypropyl)-4-(chloroaryl) piperazines as potential atypical antipsychotics. Med Chem Res 2013;22:382-91. [DOI: 10.1007/s00044-012-0038-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Kapur S. How antipsychotics become anti-‘psychotic’ – from dopamine to salience to psychosis. Trends in Pharmacological Sciences 2004;25:402-6. [DOI: 10.1016/j.tips.2004.06.005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
30 Lipina TV, Beregovoy NA, Tkachenko AA, Petrova ES, Starostina MV, Zhou Q, Li S. Uncoupling DISC1 × D2R Protein-Protein Interactions Facilitates Latent Inhibition in Disc1-L100P Animal Model of Schizophrenia and Enhances Synaptic Plasticity via D2 Receptors. Front Synaptic Neurosci 2018;10:31. [PMID: 30245624 DOI: 10.3389/fnsyn.2018.00031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Braver TS, Cohen JD. Dopamine, cognitive control, and schizophrenia: the gating model. Prog Brain Res 1999;121:327-49. [PMID: 10551035 DOI: 10.1016/s0079-6123(08)63082-4] [Cited by in Crossref: 98] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
32 Vauquelin G, Bostoen S, Vanderheyden P, Seeman P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:337-372. [PMID: 22331262 DOI: 10.1007/s00210-012-0734-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
33 Wieselgren I, Lindström LH. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Research 1998;81:101-10. [DOI: 10.1016/s0165-1781(98)00090-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
34 Locklear MN, Cohen AB, Jone A, Kritzer MF. Sex Differences Distinguish Intracortical Glutamate Receptor-Mediated Regulation of Extracellular Dopamine Levels in the Prefrontal Cortex of Adult Rats. Cereb Cortex 2016;26:599-610. [PMID: 25260707 DOI: 10.1093/cercor/bhu222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
35 Young JW, Zhou X, Geyer MA. Animal Models of Schizophrenia. In: Swerdlow NR, editor. Behavioral Neurobiology of Schizophrenia and Its Treatment. Berlin: Springer Berlin Heidelberg; 2010. pp. 391-433. [DOI: 10.1007/7854_2010_62] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
36 Vijeepallam K, Pandy V, Kunasegaran T, Murugan DD, Naidu M. Mitragyna speciosa Leaf Extract Exhibits Antipsychotic-Like Effect with the Potential to Alleviate Positive and Negative Symptoms of Psychosis in Mice. Front Pharmacol 2016;7:464. [PMID: 27999544 DOI: 10.3389/fphar.2016.00464] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
37 Featherstone RE, Burton CL, Coppa-Hopman R, Rizos Z, Sinyard J, Kapur S, Fletcher PJ. Gestational treatment with methylazoxymethanol (MAM) that disrupts hippocampal-dependent memory does not alter behavioural response to cocaine. Pharmacol Biochem Behav 2009;93:382-90. [PMID: 19467255 DOI: 10.1016/j.pbb.2009.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
38 Meyers B, Kritzer MF. In vitro binding assays using (3)H nisoxetine and (3)H WIN 35,428 reveal selective effects of gonadectomy and hormone replacement in adult male rats on norepinephrine but not dopamine transporter sites in the cerebral cortex. Neuroscience 2009;159:271-82. [PMID: 19138725 DOI: 10.1016/j.neuroscience.2008.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
39 Kim SW, Stewart R, Park WY, Jhon M, Lee JY, Kim SY, Kim JM, Amminger P, Chung YC, Yoon JS. Latent Iron Deficiency as a Marker of Negative Symptoms in Patients with First-Episode Schizophrenia Spectrum Disorder. Nutrients 2018;10:E1707. [PMID: 30412998 DOI: 10.3390/nu10111707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
40 Urs NM, Nicholls PJ, Caron MG. Integrated approaches to understanding antipsychotic drug action at GPCRs. Curr Opin Cell Biol 2014;27:56-62. [PMID: 24680431 DOI: 10.1016/j.ceb.2013.11.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
41 Hoffman RE, Mcglashan TH. Chapter 18 Using a speech perception neural network simulation to explore normal neurodevelopment and hallucinated ‘voices’ in schizophrenia. Disorders of Brain, Behavior and Cognition: The neurocomputational Perspective. Elsevier; 1999. pp. 311-25. [DOI: 10.1016/s0079-6123(08)63081-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
42 Sotoing Taïwe G, Ngo Bum E, Talla E, Dawe A, Okomolo Moto FC, Temkou Ngoupaye G, Sidiki N, Dabole B, Djomeni Dzeufiet PD, Dimo T, De Waard M. Antipsychotic and sedative effects of the leaf extract of Crassocephalum bauchiense (Hutch.) Milne-Redh (Asteraceae) in rodents. Journal of Ethnopharmacology 2012;143:213-20. [DOI: 10.1016/j.jep.2012.06.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
43 Kuepper R, Skinbjerg M, Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb Exp Pharmacol 2012;:1-26. [PMID: 23129326 DOI: 10.1007/978-3-642-25761-2_1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
44 Northoff G, Demisch L, Wenke J, Pflug B. Plasma homovanillic acid concentrations in catatonia. Biological Psychiatry 1996;39:436-43. [DOI: 10.1016/0006-3223(95)00184-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
45 Nishino N, Kitamura N, Hashimoto T, Kajimoto Y, Shirai Y, Murakami N, Nakai T, Komure O, Shirakawa O, Mita T. Increase in [3H]cAMP binding sites and decrease in Gi alpha and Go alpha immunoreactivities in left temporal cortices from patients with schizophrenia. Brain Res 1993;615:41-9. [PMID: 8395955 DOI: 10.1016/0006-8993(93)91112-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
46 Smelson DA, Ziedonis D, Williams J, Losonczy MF, Williams J, Steinberg ML, Kaune M. The Efficacy of Olanzapine for Decreasing Cue-Elicited Craving in Individuals With Schizophrenia and Cocaine Dependence: A Preliminary Report. Journal of Clinical Psychopharmacology 2006;26:9-12. [DOI: 10.1097/01.jcp.0000194624.07611.5e] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
47 Nordstrom A, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Research: Neuroimaging 1995;61:67-83. [DOI: 10.1016/0925-4927(95)02732-d] [Cited by in Crossref: 104] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
48 Ruggiero RN, Rossignoli MT, De Ross JB, Hallak JEC, Leite JP, Bueno-Junior LS. Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Front Pharmacol 2017;8:399. [PMID: 28680405 DOI: 10.3389/fphar.2017.00399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
49 Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, Davis KL. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 1993;46:151-63. [PMID: 8483974 DOI: 10.1016/0165-1781(93)90017-b] [Cited by in Crossref: 26] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
50 Chambers R, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry 2001;50:71-83. [DOI: 10.1016/s0006-3223(01)01134-9] [Cited by in Crossref: 342] [Cited by in F6Publishing: 134] [Article Influence: 17.1] [Reference Citation Analysis]
51 Amar MB, Potvin S. Cannabis and Psychosis: What is the Link? Journal of Psychoactive Drugs 2007;39:131-42. [DOI: 10.1080/02791072.2007.10399871] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
52 Bernhardt LK, Bairy KL, Madhyastha S. Neuroprotective Role of N-acetylcysteine against Learning Deficits and Altered Brain Neurotransmitters in Rat Pups Subjected to Prenatal Stress. Brain Sci 2018;8:E120. [PMID: 29958412 DOI: 10.3390/brainsci8070120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
53 Brüne M, Basilowski M, Bömmer I, Juckel G, Assion H. Machiavellianism and Executive Functioning in Patients with Delusional Disorder. Psychol Rep 2010;106:205-15. [DOI: 10.2466/pr0.106.1.205-215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
54 Tikka SK, Nizamie SH, Das B, Katshu MZ, Goyal N. Increased spontaneous gamma power and synchrony in schizophrenia patients having higher minor physical anomalies. Psychiatry Res 2013;207:164-72. [PMID: 23051885 DOI: 10.1016/j.psychres.2012.09.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
55 Bilic P, Jukic V, Vilibic M, Savic A, Bozina N. Treatment-resistant schizophrenia and DAT and SERT polymorphisms. Gene 2014;543:125-32. [PMID: 24680725 DOI: 10.1016/j.gene.2014.03.050] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
56 Zhang L, Li X, Zhou R, Xing G. Possible role of potassium channel, big K in etiology of schizophrenia. Med Hypotheses 2006;67:41-3. [PMID: 16446048 DOI: 10.1016/j.mehy.2005.09.055] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
57 Tsunoda M, Aoyama C, Nomura H, Toyoda T, Matsuki N, Funatsu T. Simultaneous determination of dopamine and 3,4-dihydroxyphenylacetic acid in mouse striatum using mixed-mode reversed-phase and cation-exchange high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 2010;51:712-5. [DOI: 10.1016/j.jpba.2009.09.045] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
58 de Wied D. Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. Eur J Pharmacol 1999;375:1-11. [PMID: 10443560 DOI: 10.1016/s0014-2999(99)00339-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
59 Power BD, Dragovic M, Jablensky A, Stefanis NC. Does accumulating exposure to illicit drugs bring forward the age at onset in schizophrenia? Aust N Z J Psychiatry 2013;47:51-8. [PMID: 23042939 DOI: 10.1177/0004867412461957] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
60 Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993;87:225-30. [PMID: 8488741 DOI: 10.1111/j.1600-0447.1993.tb03362.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 87] [Article Influence: 4.5] [Reference Citation Analysis]
61 Koychev I, Barkus E, Ettinger U, Killcross S, Roiser JP, Wilkinson L, Deakin B. Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia. J Psychopharmacol 2011;25:1207-25. [PMID: 21994315 DOI: 10.1177/0269881111414450] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
62 Leiser D, Bonshtein U. Theory of mind in schizophrenia: Damaged module or deficit in cognitive coordination? Behav Brain Sci 2003;26:95-6. [DOI: 10.1017/s0140525x03350022] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
63 Baeza I, Castro-Fornieles J, Deulofeu R, de la Serna E, Goti J, Salvà J, Bernardo M. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. Psychiatry Res 2009;168:110-8. [PMID: 19501918 DOI: 10.1016/j.psychres.2008.04.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
64 Yu Z, Fang Q, Xiao X, Wang YZ, Cai YQ, Cao H, Hu G, Chen Z, Fei J, Gong N, Xu TL. GABA transporter-1 deficiency confers schizophrenia-like behavioral phenotypes. PLoS One 2013;8:e69883. [PMID: 23922840 DOI: 10.1371/journal.pone.0069883] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
65 Ekesbo A, Torstenson R, Hartvig P, Carlsson A, Sonesson C, Waters N, Tedroff J, Långström B. Effects of the substituted (S)-3-phenylpiperidine (−)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains. Neuropharmacology 1999;38:331-8. [DOI: 10.1016/s0028-3908(98)00200-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
66 Ancoli-Israel S, Martin J, Jones DW, Caligiuri M, Patterson T, Harris MJ, Jeste DV. Sleep-disordered breathing and periodic limb movements in sleep in older patients with schizophrenia. Biol Psychiatry 1999;45:1426-32. [PMID: 10356624 DOI: 10.1016/s0006-3223(98)00166-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
67 Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;46:56-72. [PMID: 10394474 DOI: 10.1016/s0006-3223(99)00067-0] [Cited by in Crossref: 482] [Cited by in F6Publishing: 177] [Article Influence: 21.9] [Reference Citation Analysis]
68 Huntley G, Morrison J, Prikhozhan A, Sealfon S. Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum. Molecular Brain Research 1992;15:181-8. [DOI: 10.1016/0169-328x(92)90107-m] [Cited by in Crossref: 75] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
69 Opgen-Rhein C, Neuhaus AH, Urbanek C, Hahn E, Sander T, Dettling M. Executive attention in schizophrenic males and the impact of COMT Val108/158Met genotype on performance on the attention network test. Schizophr Bull 2008;34:1231-9. [PMID: 18199630 DOI: 10.1093/schbul/sbm155] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
70 O‚donnell P, Grace AA. Basic Neurophysiology of Antipsychotic Drug Action. In: Csernansky JG, editor. Antipsychotics. Berlin: Springer Berlin Heidelberg; 1996. pp. 163-202. [DOI: 10.1007/978-3-642-61007-3_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
71 Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014;19:20-29. [PMID: 24166406 DOI: 10.1038/mp.2013.136] [Cited by in Crossref: 139] [Cited by in F6Publishing: 113] [Article Influence: 17.4] [Reference Citation Analysis]
72 Qin Y, Wang N, Zhang X, Han X, Zhai X, Lu Y. IDO and TDO as a potential therapeutic target in different types of depression. Metab Brain Dis 2018;33:1787-800. [PMID: 30014175 DOI: 10.1007/s11011-018-0290-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
73 McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends Neurosci 2019;42:205-20. [PMID: 30621912 DOI: 10.1016/j.tins.2018.12.004] [Cited by in Crossref: 162] [Cited by in F6Publishing: 115] [Article Influence: 81.0] [Reference Citation Analysis]
74 Bouwmeester H, Wolterink G, van Ree JM. Neonatal development of projections from the basolateral amygdala to prefrontal, striatal, and thalamic structures in the rat. J Comp Neurol 2002;442:239-49. [PMID: 11774339 DOI: 10.1002/cne.10084] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
75 Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, Turkheimer F. Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain. 2013;136:3242-3251. [PMID: 24097339 DOI: 10.1093/brain/awt264] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 11.8] [Reference Citation Analysis]
76 Leysen JE. Receptor profile of antipsychotics. In: Ellenbroek BA, Cools AR, editors. Atypical Antipsychotics. Basel: Birkhäuser; 2000. pp. 57-81. [DOI: 10.1007/978-3-0348-8448-8_4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
77 Brambilla F, Marini S, Saito A, Fassone G, Picardi A, Nerozzi D, Pancheri P. Noradrenergic and dopaminergic interrelation in schizophrenia. Psychiatry Research 1994;53:231-42. [DOI: 10.1016/0165-1781(94)90052-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
78 Servonnet A, Minogianis E, Bouchard C, Bédard A, Lévesque D, Rompré P, Samaha A. Neurotensin in the nucleus accumbens reverses dopamine supersensitivity evoked by antipsychotic treatment. Neuropharmacology 2017;123:10-21. [DOI: 10.1016/j.neuropharm.2017.05.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
79 Ball S, Busatto GF, David AS, Jones SH, Hemsley DR, Pilowsky LS, Costa DC, Ell PJ, Kerwin RW. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. Biol Psychiatry 1998;43:107-17. [PMID: 9474443 DOI: 10.1016/s0006-3223(97)00300-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
80 Kapur S. Receptor Occupancy by Antipsychotics — Concepts and Findings. In: Lidow M, editor. Neurotransmitter Receptors in Actions of Antipsychotic Medications. CRC Press; 2000. pp. 163-76. [DOI: 10.1201/9781420041774.ch11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
81 Foster DJ, Choi DL, Conn PJ, Rook JM. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. Neuropsychiatr Dis Treat 2014;10:183-91. [PMID: 24511233 DOI: 10.2147/NDT.S55104] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
82 Kohler CG, Martin EA, Kujawski E, Bilker W, Gur RE, Gur RC. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry 2007;12:412-21. [PMID: 17690999 DOI: 10.1080/13546800701307263] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
83 Harris MJ, Mcadams LA, Heaton SC. Negative Symptoms in Late‐Life Schizophrenia. The American Journal of Geriatric Psychiatry 1994;2:9-20. [DOI: 10.1097/00019442-199400210-00004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
84 Liu C, Bousman CA, Pantelis C, Skafidas E, Zhang D, Yue W, Everall IP. Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations. Transl Psychiatry 2017;7:e1037. [PMID: 28221366 DOI: 10.1038/tp.2017.8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
85 Russo M, Carrarini C, Dono F, Rispoli MG, Di Pietro M, Di Stefano V, Ferri L, Bonanni L, Sensi SL, Onofrj M. The Pharmacology of Visual Hallucinations in Synucleinopathies. Front Pharmacol 2019;10:1379. [PMID: 31920635 DOI: 10.3389/fphar.2019.01379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
86 Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28 Suppl 1:53-67. [PMID: 12504072 DOI: 10.1016/s0306-4530(02)00112-9] [Cited by in Crossref: 139] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
87 Ľupták M, Michaličková D, Fišar Z, Kitzlerová E, Hroudová J. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J Psychiatry 2021;11:277-96. [PMID: 34327122 DOI: 10.5498/wjp.v11.i7.277] [Reference Citation Analysis]
88 Ohnuma T, Nishimon S, Takeda M, Sannohe T, Katsuta N, Arai H. Carbonyl Stress and Microinflammation-Related Molecules as Potential Biomarkers in Schizophrenia. Front Psychiatry 2018;9:82. [PMID: 29593588 DOI: 10.3389/fpsyt.2018.00082] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
89 Shi W, Zhang X, Pun C, Bunney BS. Clozapine Blocks D-Amphetamine-Induced Excitation of Dopamine Neurons in the Ventral Tegmental Area. Neuropsychopharmacol 2007;32:1922-8. [DOI: 10.1038/sj.npp.1301334] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
90 Assié M, Sleight AJ, Koek W. Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. European Journal of Pharmacology 1993;237:183-9. [DOI: 10.1016/0014-2999(93)90267-l] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Yadav P, Manivannan S, Kim H, Pandey K, Kim K, Kim J. Electrochemical Properties of Highly Sensitive and Selective CuO Nanostructures Based Neurotransmitter Dopamine Sensor. Electroanalysis 2017;29:2106-13. [DOI: 10.1002/elan.201700195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
92 Taheri RA, Eskandari K, Negahdary M. An electrochemical dopamine aptasensor using the modified Au electrode with spindle-shaped gold nanostructure. Microchemical Journal 2018;143:243-51. [DOI: 10.1016/j.microc.2018.08.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
93 Syvälahti EKG. Biological Factors in Schizophrenia Structural and Functional Aspects. Br J Psychiatry 1994;164:9-14. [DOI: 10.1192/s0007125000292672] [Cited by in Crossref: 17] [Article Influence: 5.7] [Reference Citation Analysis]
94 Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1556-1571. [PMID: 17884274 DOI: 10.1016/j.pnpbp.2007.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 116] [Article Influence: 9.4] [Reference Citation Analysis]
95 Silverstein SM. Visual Perception Disturbances in Schizophrenia: A Unified Model. Nebr Symp Motiv 2016;63:77-132. [PMID: 27627825 DOI: 10.1007/978-3-319-30596-7_4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
96 Fricchione GL, Carbone L, Bennett WI. Psychotic Disorder Caused by a General Medical Condition, with Delusions. Psychiatric Clinics of North America 1995;18:363-78. [DOI: 10.1016/s0193-953x(18)30060-1] [Cited by in Crossref: 19] [Article Influence: 0.7] [Reference Citation Analysis]
97 Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002;22:3708-19. [PMID: 11978847 DOI: 20026302] [Cited by in F6Publishing: 196] [Reference Citation Analysis]
98 Laruelle M. The second revision of the dopamine theory of schizophrenia: implications for treatment and drug development. Biol Psychiatry 2013;74:80-1. [PMID: 23809260 DOI: 10.1016/j.biopsych.2013.05.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
99 D'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, Pittman B, Ranganathan M, Cosgrove K, Staley J. Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry 2012;169:326-34. [PMID: 22193533 DOI: 10.1176/appi.ajp.2011.11020189] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
100 Wu Z, Zhang XY, Wang H, Tang W, Xia Y, Zhang F, Liu J, Fu Y, Hu J, Chen Y, Liu L, Chen DC, Xiu MH, Kosten TR, He J. Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2012;36:34-8. [DOI: 10.1016/j.pnpbp.2011.08.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
101 Bierer LM, Knott PJ, Schmeidler JM, Marin DB, Ryan TM, Haroutunian V, Purohit DP, Perl DP, Mohs RC, Davis KL. Post-mortem examination of dopaminergic parameters in Alzheimer's disease: Relationship to noncognitive symptoms. Psychiatry Research 1993;49:211-7. [DOI: 10.1016/0165-1781(93)90062-l] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
102 Adell A, Artigas F. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev 2004;28:415-31. [PMID: 15289006 DOI: 10.1016/j.neubiorev.2004.05.001] [Cited by in Crossref: 117] [Cited by in F6Publishing: 110] [Article Influence: 6.9] [Reference Citation Analysis]
103 Jentsch J, Taylor J, Elsworth J, Redmond D, Roth R. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neuroscience 1999;90:823-32. [DOI: 10.1016/s0306-4522(98)00481-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
104 Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002;325:1199. [PMID: 12446534 DOI: 10.1136/bmj.325.7374.1199] [Cited by in Crossref: 507] [Cited by in F6Publishing: 364] [Article Influence: 26.7] [Reference Citation Analysis]
105 Maria K, Charalampos T, Vassilakopoulou D, Stavroula S, Vasiliki K, Nikolaos D. Frequency Distribution of COMT Polymorphisms in Greek Patients with Schizophrenia and Controls: A Study of SNPs rs737865, rs4680, and rs165599. ISRN Psychiatry 2012;2012:651613. [PMID: 23762769 DOI: 10.5402/2012/651613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
106 Oranje B, Gispen-de Wied CC, Westenberg HGM, Kemner C, Verbaten MN, Kahn RS. Increasing Dopaminergic Activity: Effects of L-Dopa and Bromocriptine on Human Sensory Gating. J Psychopharmacol 2004;18:388-94. [DOI: 10.1177/026988110401800310] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
107 Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004;174:3-16. [PMID: 15118803 DOI: 10.1007/s00213-004-1793-y] [Cited by in Crossref: 288] [Cited by in F6Publishing: 278] [Article Influence: 16.9] [Reference Citation Analysis]
108 Kumar SA, Wang S, Yang TC, Yeh C. Acid yellow 9 as a dispersing agent for carbon nanotubes: Preparation of redox polymer–carbon nanotube composite film and its sensing application towards ascorbic acid and dopamine. Biosensors and Bioelectronics 2010;25:2592-7. [DOI: 10.1016/j.bios.2010.04.024] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
109 Fyfe TJ, Scammells PJ, Lane JR, Capuano B. Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor. Molecules 2021;26:3799. [PMID: 34206465 DOI: 10.3390/molecules26133799] [Reference Citation Analysis]
110 Magioncalda P, Martino M, Conio B, Lee HC, Ku HL, Chen CJ, Inglese M, Amore M, Lane TJ, Northoff G. Intrinsic brain activity of subcortical-cortical sensorimotor system and psychomotor alterations in schizophrenia and bipolar disorder: A preliminary study. Schizophr Res 2020;218:157-65. [PMID: 32029353 DOI: 10.1016/j.schres.2020.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
111 Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69-108. [PMID: 17349858 DOI: 10.1016/s0074-7742(06)78003-5] [Cited by in Crossref: 363] [Cited by in F6Publishing: 189] [Article Influence: 30.3] [Reference Citation Analysis]
112 Chang H, Lu R, Lin W, Chang C, Chen C, Shy M, Huang S. Lack of association between dopamine D3 receptor Ser9Gly polymorphism and schizophrenia in Han Chinese population. Acta Neuropsychiatr 2007;19:344-50. [DOI: 10.1111/j.1601-5215.2007.00214.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
113 Lataster J, Collip D, Ceccarini J, Hernaus D, Haas D, Booij L, van Os J, Pruessner J, Van Laere K, Myin-Germeys I. Familial liability to psychosis is associated with attenuated dopamine stress signaling in ventromedial prefrontal cortex. Schizophr Bull 2014;40:66-77. [PMID: 23363687 DOI: 10.1093/schbul/sbs187] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
114 Griffiths O, Langdon R, Le Pelley ME, Coltheart M. Delusions and prediction error: re-examining the behavioural evidence for disrupted error signalling in delusion formation. Cogn Neuropsychiatry 2014;19:439-67. [PMID: 24702287 DOI: 10.1080/13546805.2014.897601] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
115 Gardner RJ, Kersanté F, Jones MW, Bartsch U. Neural oscillations during non-rapid eye movement sleep as biomarkers of circuit dysfunction in schizophrenia. Eur J Neurosci 2014;39:1091-106. [DOI: 10.1111/ejn.12533] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
116 Gao WJ, Wang Y, Goldman-Rakic PS. Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. J Neurosci 2003;23:1622-30. [PMID: 12629166 [PMID: 12629166 DOI: 10.1523/jneurosci.23-05-01622.2003] [Cited by in Crossref: 88] [Article Influence: 4.9] [Reference Citation Analysis]
117 Baldessarini RJ. Dopamine Receptors and Clinical Medicine. In: Neve KA, Neve RL, editors. The Dopamine Receptors. Totowa: Humana Press; 1997. pp. 457-98. [DOI: 10.1007/978-1-4757-2635-0_15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
118 De Murtas M, Tatarelli R, Girardi P, Vicini S. Repeated electroconvulsive stimulation impairs long-term depression in the neostriatum. Biological Psychiatry 2004;55:472-6. [DOI: 10.1016/j.biopsych.2003.11.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
119 De Deurwaerdère P, Di Giovanni G. Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications. Prog Neurobiol 2017;151:175-236. [PMID: 27013075 DOI: 10.1016/j.pneurobio.2016.03.004] [Cited by in Crossref: 96] [Cited by in F6Publishing: 66] [Article Influence: 19.2] [Reference Citation Analysis]
120 Badawy A. Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide. Psychopharmacology (Berl) 2013;228:347-58. [PMID: 23828158 DOI: 10.1007/s00213-013-3191-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
121 Dyck BA, Skoblenick KJ, Castellano JM, Ki K, Thomas N, Mishra RK. Behavioral abnormalities in synapsin II knockout mice implicate a causal factor in schizophrenia. Synapse. 2009;63:662-672. [PMID: 19360855 DOI: 10.1002/syn.20643] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
122 Slifstein M, Abi-Dargham A. Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders. Semin Nucl Med 2017;47:54-63. [PMID: 27987558 DOI: 10.1053/j.semnuclmed.2016.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
123 Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, Gallego JA, Kane JM, Szeszko PR, Malhotra AK. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA Psychiatry 2015;72:5-13. [PMID: 25372846 DOI: 10.1001/jamapsychiatry.2014.1734] [Cited by in Crossref: 188] [Cited by in F6Publishing: 131] [Article Influence: 31.3] [Reference Citation Analysis]
124 Levant B, Ozias MK, Carlson SE. Sex-specific effects of brain LC-PUFA composition on locomotor activity in rats. Physiology & Behavior 2006;89:196-204. [DOI: 10.1016/j.physbeh.2006.06.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
125 Sun Y, Farzan F, Barr MS, Kirihara K, Fitzgerald PB, Light GA, Daskalakis ZJ. Gamma oscillations in schizophrenia: Mechanisms and clinical significance. Brain Research 2011;1413:98-114. [DOI: 10.1016/j.brainres.2011.06.065] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 6.5] [Reference Citation Analysis]
126 Green AI, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME, Tsuang MT, Schildkraut JJ. Haloperidol response and plasma catecholamines and their metabolites. Schizophrenia Research 1993;10:33-7. [DOI: 10.1016/0920-9964(93)90074-s] [Cited by in Crossref: 24] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
127 Chen EY. A Neural Network Model of Cortical Information Processing in Schizophrenia. I: Interaction between Biological and Social Factors in Symptom Formation. Can J Psychiatry 1994;39:362-7. [DOI: 10.1177/070674379403900803] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
128 Kirschner M, Schmidt A, Hodzic-Santor B, Burrer A, Manoliu A, Zeighami Y, Yau Y, Abbasi N, Maatz A, Habermeyer B, Abivardi A, Avram M, Brandl F, Sorg C, Homan P, Riecher-Rössler A, Borgwardt S, Seifritz E, Dagher A, Kaiser S. Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum. Schizophr Bull 2021;47:849-63. [PMID: 33257954 DOI: 10.1093/schbul/sbaa169] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Phan SV, Kreys TM. Adjunct Mirtazapine for Negative Symptoms of Schizophrenia. Pharmacotherapy 2011;31:1017-30. [DOI: 10.1592/phco.31.10.1017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
130 Schl�sser R, Schlegel S. D2-receptor imaging with [123I]IBZM and Single Photon Emission Tomography in psychiatry: a survey of current status. J Neural Transmission 1995;99:173-85. [DOI: 10.1007/bf01271477] [Cited by in Crossref: 11] [Article Influence: 0.4] [Reference Citation Analysis]
131 Berry MD, Juorio AV, Paterson IA. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol 1994;44:141-61. [PMID: 7831475 DOI: 10.1016/0301-0082(94)90036-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.2] [Reference Citation Analysis]
132 Moskovitz J, Walss-Bass C, Cruz DA, Thompson PM, Bortolato M. Methionine sulfoxide reductase regulates brain catechol-O-methyl transferase activity. Int J Neuropsychopharmacol 2014;17:1707-13. [PMID: 24735585 DOI: 10.1017/S1461145714000467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
133 Horga G, Fernández-Egea E, Mané A, Font M, Schatz KC, Falcon C, Lomeña F, Bernardo M, Parellada E. Brain metabolism during hallucination-like auditory stimulation in schizophrenia. PLoS One 2014;9:e84987. [PMID: 24416328 DOI: 10.1371/journal.pone.0084987] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
134 Fujii DE, Ahmed I. Is Psychosis a Neurobiological Syndrome? Can J Psychiatry 2004;49:713-8. [DOI: 10.1177/070674370404901101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
135 Xu H, Yang HJ, Rose GM, Li XM. Recovery of behavioral changes and compromised white matter in C57BL/6 mice exposed to cuprizone: effects of antipsychotic drugs. Front Behav Neurosci 2011;5:31. [PMID: 21747763 DOI: 10.3389/fnbeh.2011.00031] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
136 Tonelli HA. How semantic deficits in schizotypy help understand language and thought disorders in schizophrenia: a systematic and integrative review. Trends Psychiatry Psychother 2014;36:75-88. [DOI: 10.1590/2237-6089-2013-0053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
137 Sonibare MA, Umukoro S, Shonibare ET. Antipsychotic property of aqueous and ethanolic extracts of Lonchocarpus cyanescens (Schumach and Thonn.) Benth. (Fabaceae) in rodents. J Nat Med 2012;66:127-32. [DOI: 10.1007/s11418-011-0562-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
138 Khomane KS, Meena CL, Jain R, Bansal AK. Novel thyrotropin-releasing hormone analogs: a patent review. Expert Opin Ther Pat 2011;21:1673-91. [PMID: 22017410 DOI: 10.1517/13543776.2011.623127] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
139 Gray N, Pickering A, Gray J, Jones S, Abrahams S, Hemsley D. Kamin blocking is not disrupted by amphetamine in human subjects. J Psychopharmacol 1997;11:301-11. [DOI: 10.1177/026988119701100404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
140 Seeman MV. History of the dopamine hypothesis of antipsychotic action. World J Psychiatry 2021;11:355-64. [PMID: 34327128 DOI: 10.5498/wjp.v11.i7.355] [Reference Citation Analysis]
141 Mueller HT, Haroutunian V, Davis KL, Meador-woodruff JH. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Molecular Brain Research 2004;121:60-9. [DOI: 10.1016/j.molbrainres.2003.11.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 3.5] [Reference Citation Analysis]
142 Jönsson EG, Ivo R, Forslund K, Mattila-Evenden M, Rylander G, Cichon S, Propping P, Nöthen MM, Asberg M, Sedvall GC. No association between a promoter dopamine D(4) receptor gene variant and schizophrenia. Am J Med Genet 2001;105:525-8. [PMID: 11496369 DOI: 10.1002/ajmg.1478] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
143 Stip E, Cherbal A, Luck D, Zhornitsky S, Bentaleb LA, Lungu O. A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment. Psychopharmacology (Berl) 2017;234:1045-58. [PMID: 28210783 DOI: 10.1007/s00213-017-4533-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Boldrini M, Placidi GPA, Marazziti D. Applications of Chaos Theories to Psychiatry: A Review and Future Perspectives. CNS spectr 1998;3:22-9. [DOI: 10.1017/s1092852900005356] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
145 Zhang L, Xu S, Huang Q, Xu H. N-acetylcysteine attenuates the cuprizone-induced behavioral changes and oligodendrocyte loss in male C57BL/7 mice via its anti-inflammation actions. J Neuro Res 2018;96:803-16. [DOI: 10.1002/jnr.24189] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
146 Mann SC, Caroff SN, Fricchione G, Campbell EC. Central Dopamine Hypoactivity and the Pathogenesis of Neuroleptic Malignant Syndrome. Psychiatric Annals 2000;30:363-74. [DOI: 10.3928/0048-5713-20000501-14] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
147 Peleg-raibstein D, Knuesel I, Feldon J. Amphetamine sensitization in rats as an animal model of schizophrenia. Behavioural Brain Research 2008;191:190-201. [DOI: 10.1016/j.bbr.2008.03.037] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
148 Hosák L, Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry 2002;17:371-8. [PMID: 12547302 DOI: 10.1016/s0924-9338(02)00696-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
149 Kaptsan A, Dwolatzky T, Lerner V. Ziprasidone-associated depressive state in schizophrenic patients. Clin Neuropharmacol 2007;30:357-61. [PMID: 18090461 DOI: 10.1097/wnf.0b013e31805751a3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
150 Schwartz BD, Evans WJ, Pena JM, Winstead DK. Visible persistence decay rates for schizophrenics and substance abusers. Biological Psychiatry 1994;36:662-9. [DOI: 10.1016/0006-3223(94)91175-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
151 Tomasella E, Bechelli L, Ogando MB, Mininni C, Di Guilmi MN, De Fino F, Zanutto S, Elgoyhen AB, Marin-Burgin A, Gelman DM. Deletion of dopamine D2 receptors from parvalbumin interneurons in mouse causes schizophrenia-like phenotypes. Proc Natl Acad Sci U S A 2018;115:3476-81. [PMID: 29531031 DOI: 10.1073/pnas.1719897115] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
152 Cirulli F, Bonsignore L, Venerosi A, Valanzano A, Chiarotti F, Alleva E. Long-term effects of acute perinatal asphyxia on rat maternal behavior. Neurotoxicology and Teratology 2003;25:571-8. [DOI: 10.1016/s0892-0362(03)00035-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
153 Rajagopal L, Massey BW, Michael E, Meltzer HY. Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice. Psychopharmacology 2016;233:649-60. [DOI: 10.1007/s00213-015-4137-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
154 Stojanovic T, Orlova M, Sialana FJ, Höger H, Stuchlik S, Milenkovic I, Aradska J, Lubec G. Validation of dopamine receptor DRD1 and DRD2 antibodies using receptor deficient mice. Amino Acids 2017;49:1101-9. [PMID: 28316027 DOI: 10.1007/s00726-017-2408-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
155 Lyon L, Saksida LM, Bussey TJ. Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacology 2012;220:647-72. [DOI: 10.1007/s00213-011-2536-5] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 7.9] [Reference Citation Analysis]
156 Jaskiw GE, Weinberger DR. Dopamine and schizophrenia—a cortically corrective perspective. Seminars in Neuroscience 1992;4:179-88. [DOI: 10.1016/1044-5765(92)90016-u] [Cited by in Crossref: 40] [Article Influence: 1.4] [Reference Citation Analysis]
157 Soliman A, O'Driscoll GA, Pruessner J, Holahan AL, Boileau I, Gagnon D, Dagher A. Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study. Neuropsychopharmacology 2008;33:2033-41. [PMID: 17957215 DOI: 10.1038/sj.npp.1301597] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 6.7] [Reference Citation Analysis]
158 Betts JF, Schweimer JV, Burnham KE, Burnet PW, Sharp T, Harrison PJ. D-amino acid oxidase is expressed in the ventral tegmental area and modulates cortical dopamine. Front Synaptic Neurosci 2014;6:11. [PMID: 24822045 DOI: 10.3389/fnsyn.2014.00011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
159 Condray R, Steinhauer SR. Mechanisms of disrupted language comprehension in schizophrenia. Behav Brain Sci 2003;26:87-8. [DOI: 10.1017/s0140525x03270023] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
160 Vreeker A, van Bergen AH, Kahn RS. Cognitive enhancing agents in schizophrenia and bipolar disorder. European Neuropsychopharmacology 2015;25:969-1002. [DOI: 10.1016/j.euroneuro.2015.04.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
161 Sestito RS, Trindade LB, de Souza RG, Kerbauy LN, Iyomasa MM, Rosa ML. Effect of isolation rearing on the expression of AMPA glutamate receptors in the hippocampal formation. J Psychopharmacol 2011;25:1720-9. [DOI: 10.1177/0269881110385595] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
162 Tuppurainen H, Kuikka JT, Viinamäki H, Husso M, Tiihonen J. Dopamine D 2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry and Clinical Neurosciences 2009;63:529-37. [DOI: 10.1111/j.1440-1819.2009.01982.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
163 Moncrieff J. A critique of the dopamine hypothesis of schizophrenia and psychosis. Harv Rev Psychiatry. 2009;17:214-225. [PMID: 19499420 DOI: 10.1080/10673220902979896] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
164 Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33:1120-30. [PMID: 17641146 DOI: 10.1093/schbul/sbm083] [Cited by in Crossref: 133] [Cited by in F6Publishing: 117] [Article Influence: 9.5] [Reference Citation Analysis]
165 Manzella F, Maloney SE, Taylor GT. Smoking in schizophrenic patients: A critique of the self-medication hypothesis. World J Psychiatry 2015;5:35-46. [PMID: 25815253 DOI: 10.5498/wjp.v5.i1.35] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
166 Edut S, Rubovitch V, Rehavi M, Schreiber S, Pick CG. A study on the mechanism by which MDMA protects against dopaminergic dysfunction after minimal traumatic brain injury (mTBI) in mice. J Mol Neurosci 2014;54:684-97. [PMID: 25124230 DOI: 10.1007/s12031-014-0399-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
167 Zhou Z, Liu X, Chen S, Zhang Z, Liu Y, Montardy Q, Tang Y, Wei P, Liu N, Li L, Song R, Lai J, He X, Chen C, Bi G, Feng G, Xu F, Wang L. A VTA GABAergic Neural Circuit Mediates Visually Evoked Innate Defensive Responses. Neuron 2019;103:473-488.e6. [PMID: 31202540 DOI: 10.1016/j.neuron.2019.05.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 24] [Article Influence: 25.0] [Reference Citation Analysis]
168 Bogaert AVD, Del-favero J, Broeckhoven CV. Major affective disorders and schizophrenia: a common molecular signature? Hum Mutat 2006;27:833-53. [DOI: 10.1002/humu.20369] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
169 Galderisi S, Merlotti E, Mucci A. Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci 2015;265:543-58. [PMID: 25797499 DOI: 10.1007/s00406-015-0590-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
170 Hedou G, Homberg J, Feldon J, Heidbreder CA. Expression of sensitization to amphetamine and dynamics of dopamine neurotransmission in different laminae of the rat medial prefrontal cortex. Neuropharmacology 2001;40:366-82. [DOI: 10.1016/s0028-3908(00)00174-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
171 Chong VZ, Young LT, Mishra RK. cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. J Neurochem. 2002;82:1533-1539. [PMID: 12354301 DOI: 10.1046/j.1471-4159.2002.01104.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
172 Watari M, Hamazaki K, Hirata T, Hamazaki T, Okubo Y. Hostility of drug-free patients with schizophrenia and n−3 polyunsaturated fatty acid levels in red blood cells. Psychiatry Research 2010;177:22-6. [DOI: 10.1016/j.psychres.2010.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
173 Wang HD, Deutch AY. Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology 2008;33:1276-86. [PMID: 17687264 DOI: 10.1038/sj.npp.1301521] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
174 Gemperle AY, McAllister KH, Olpe HR. Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm. Psychopharmacology (Berl) 2003;169:354-64. [PMID: 12827343 DOI: 10.1007/s00213-003-1459-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
175 Robinson RG, Smith SM, Wolkenberg SE, Kandebo M, Yao L, Gibson CR, Harrison ST, Polsky-Fisher S, Barrow JC, Manley PJ, Mulhearn JJ, Nanda KK, Schubert JW, Trotter BW, Zhao Z, Sanders JM, Smith RF, McLoughlin D, Sharma S, Hall DL, Walker TL, Kershner JL, Bhandari N, Hutson PH, Sachs NA. Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates. ACS Chem Neurosci 2012;3:129-40. [PMID: 22860182 DOI: 10.1021/cn200109w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
176 Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken JB, Gersons BP, van Royen EA. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophrenia Research 2001;47:59-67. [DOI: 10.1016/s0920-9964(00)00023-2] [Cited by in Crossref: 59] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
177 David Jentsch J, Roth R. Effects of Antipsychotic Drugs on Dopamine Release and Metabolism in the Central Nervous System. In: Lidow M, editor. Neurotransmitter Receptors in Actions of Antipsychotic Medications. CRC Press; 2000. pp. 31-41. [DOI: 10.1201/9781420041774.ch3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
178 Kopinathan A, Scammells PJ, Lane JR, Capuano B. Multivalent approaches and beyond: novel tools for the investigation of dopamine D 2 receptor pharmacology. Future Medicinal Chemistry 2016;8:1349-72. [DOI: 10.4155/fmc-2016-0010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
179 Bachiller A, Lubeiro A, Díez Á, Suazo V, Domínguez C, Blanco JA, Ayuso M, Hornero R, Poza J, Molina V. Decreased entropy modulation of EEG response to novelty and relevance in schizophrenia during a P300 task. Eur Arch Psychiatry Clin Neurosci 2015;265:525-35. [DOI: 10.1007/s00406-014-0525-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
180 Aubele T, Kritzer MF. Gonadectomy and hormone replacement affects in vivo basal extracellular dopamine levels in the prefrontal cortex but not motor cortex of adult male rats. Cereb Cortex 2011;21:222-32. [PMID: 20466748 DOI: 10.1093/cercor/bhq083] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
181 Belzung C, Leguisquet A, Barreau S, Delion-vancassel S, Chalon S, Durand G. α-Linolenic Acid Deficiency Modifies Distractibility but Not Anxiety and Locomotion in Rats during Aging. The Journal of Nutrition 1998;128:1537-42. [DOI: 10.1093/jn/128.9.1537] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
182 Fyfe TJ, Zarzycka B, Lim HD, Kellam B, Mistry SN, Katrich V, Scammells PJ, Lane JR, Capuano B. A Thieno[2,3- d ]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D 2 Receptor. J Med Chem 2019;62:174-206. [DOI: 10.1021/acs.jmedchem.7b01565] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
183 Adams W, Ayton S, van den Buuse M. Serotonergic lesions of the dorsal hippocampus differentially modulate locomotor hyperactivity induced by drugs of abuse in rats: implications for schizophrenia. Psychopharmacology 2009;206:665-76. [DOI: 10.1007/s00213-009-1617-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
184 Campbell M, Gonzalez NM, Ernst M, Silva RR, Werry JS. Antipsychotics (Neuroleptics). In: Werry JS, Aman MG, editors. Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. Boston: Springer US; 1993. pp. 269-96. [DOI: 10.1007/978-1-4615-2884-5_10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
185 Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biological Psychiatry 1999;45:1-16. [DOI: 10.1016/s0006-3223(98)00287-x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
186 Bitanihirwe BK, Peleg-Raibstein D, Mouttet F, Feldon J, Meyer U. Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 2010;35:2462-78. [PMID: 20736993 DOI: 10.1038/npp.2010.129] [Cited by in Crossref: 151] [Cited by in F6Publishing: 145] [Article Influence: 13.7] [Reference Citation Analysis]
187 Brown RW, Perna MK, Maple AM, Wilson TD, Miller BE. Adulthood olanzapine treatment fails to alleviate decreases of ChAT and BDNF RNA expression in rats quinpirole-primed as neonates. Brain Research 2008;1200:66-77. [DOI: 10.1016/j.brainres.2008.01.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
188 Leweke FM, Mueller JK, Lange B, Fritze S, Topor CE, Koethe D, Rohleder C. Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. CNS Drugs 2018;32:605-19. [DOI: 10.1007/s40263-018-0539-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
189 Bigliani V, Pilowsky LS. In vivo neuropharmacology of schizophrenia. Br J Psychiatry 1999;174:23-33. [DOI: 10.1192/s0007125000298085] [Cited by in Crossref: 9] [Article Influence: 3.0] [Reference Citation Analysis]
190 Almulla AF, Al-Hakeim HK, Maes M. Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia. CNS Spectr 2021;26:368-77. [PMID: 32431263 DOI: 10.1017/S1092852920001182] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
191 Eaton ME, Macías W, Youngs RM, Rajadhyaksha A, Dudman JT, Konradi C. L-type Ca2+ channel blockers promote Ca2+ accumulation when dopamine receptors are activated in striatal neurons. Brain Res Mol Brain Res 2004;131:65-72. [PMID: 15530653 DOI: 10.1016/j.molbrainres.2004.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
192 Li Q, Zhang B, Cao H, Liu W, Guo F, Shen F, Ye B, Liu H, Li Y, Liu Z. Oxytocin Exerts Antidepressant-like effect by potentiating dopaminergic synaptic transmission in the mPFC. Neuropharmacology 2020;162:107836. [PMID: 31682854 DOI: 10.1016/j.neuropharm.2019.107836] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
193 Abo-Al-Ela HG. Toxoplasmosis and Psychiatric and Neurological Disorders: A Step toward Understanding Parasite Pathogenesis. ACS Chem Neurosci 2020;11:2393-406. [PMID: 31268676 DOI: 10.1021/acschemneuro.9b00245] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
194 Vineesh TV, Alwarappan S, Narayanan TN. The improved electrochemical performance of cross-linked 3D graphene nanoribbon monolith electrodes. Nanoscale 2015;7:6504-9. [DOI: 10.1039/c4nr07315k] [Cited by in Crossref: 23] [Cited by in F6Publishing: 1] [Article Influence: 3.8] [Reference Citation Analysis]
195 Coppa-Hopman R, Galle J, Pimkine D. D1 receptor antagonist-induced long-term depression in the medial prefrontal cortex of rat, in vivo: an animal model of psychiatric hypofrontality. J Psychopharmacol 2009;23:672-85. [PMID: 18635697 DOI: 10.1177/0269881108091256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
196 Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997;11:123-31. [PMID: 9208376 DOI: 10.1177/026988119701100205] [Cited by in Crossref: 190] [Cited by in F6Publishing: 169] [Article Influence: 7.9] [Reference Citation Analysis]
197 Brust P, Bauer R, Walter B, Bergmann R, Füchtner F, Vorwieger G, Steinbach J, Johannsen B, Zwiener U. Simultaneous measurement of [ 18 F]FDOPA metabolism and cerebral blood flow in newborn piglets. Int j dev neurosci 2000;16:353-64. [DOI: 10.1016/s0736-5748(98)00017-3] [Cited by in Crossref: 10] [Article Influence: 0.5] [Reference Citation Analysis]
198 Egashira N, Tanoue A, Higashihara F, Fuchigami H, Sano K, Mishima K, Fukue Y, Nagai H, Takano Y, Tsujimoto G, Stemmelin J, Griebel G, Iwasaki K, Ikeda T, Nishimura R, Fujiwara M. Disruption of the Prepulse Inhibition of the Startle Reflex in Vasopressin V1b Receptor Knockout Mice: Reversal by Antipsychotic Drugs. Neuropsychopharmacol 2005;30:1996-2005. [DOI: 10.1038/sj.npp.1300784] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
199 Amoah SK, Rodriguez BA, Logothetis CN, Chander P, Sellgren CM, Weick JP, Sheridan SD, Jantzie LL, Webster MJ, Mellios N. Exosomal secretion of a psychosis-altered miRNA that regulates glutamate receptor expression is affected by antipsychotics. Neuropsychopharmacology 2020;45:656-65. [PMID: 31775160 DOI: 10.1038/s41386-019-0579-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
200 Hui L, Han M, Yin GZ, Zhang Y, Huang XF, Qian ZK, Gu WG, Gu XC, Zhu XM, Soares JC, Ning Y, Zheng Y, Du XD, Zhang XY. Association between DBH 19 bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia. Schizophrenia Research 2017;182:104-9. [DOI: 10.1016/j.schres.2016.10.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
201 Trestman RL, Keefe RS, Mitropoulou V, Harvey PD, deVegvar ML, Lees-Roitman S, Davidson M, Aronson A, Silverman J, Siever LJ. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Res 1995;59:127-36. [PMID: 8771227 DOI: 10.1016/0165-1781(95)02709-2] [Cited by in Crossref: 87] [Cited by in F6Publishing: 68] [Article Influence: 3.5] [Reference Citation Analysis]
202 Taylor SF, Phan KL, Britton JC, Liberzon I. Neural response to emotional salience in schizophrenia. Neuropsychopharmacology 2005;30:984-95. [PMID: 15689961 DOI: 10.1038/sj.npp.1300679] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 6.6] [Reference Citation Analysis]
203 Levitt JJ, Rosow LK, Nestor PG, Pelavin PE, Swisher TM, Mccarley RW, Shenton ME. A volumetric MRI study of limbic, associative and sensorimotor striatal subregions in schizophrenia. Schizophrenia Research 2013;145:11-9. [DOI: 10.1016/j.schres.2012.08.032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
204 Spring B. Cognitive Alterations as Markers of Vulnerability to Schizophrenia. Ann NY Acad Sci 1992;658:128-45. [DOI: 10.1111/j.1749-6632.1992.tb22842.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
205 Dawirs RR, Teuchert-Noodt G, Czaniera R. Ontogeny of PFC-related behaviours is sensitive to a single non-invasive dose of methamphetamine in neonatal gerbils (Meriones unguiculatus). J Neural Transm (Vienna) 1996;103:1235-45. [PMID: 9013410 DOI: 10.1007/BF01271184] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
206 Catapano LA, Manji HK. G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta 2007;1768:976-93. [PMID: 17078926 DOI: 10.1016/j.bbamem.2006.09.025] [Cited by in Crossref: 72] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
207 Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K, Kaneko S. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000;10:335-41. [PMID: 10862524 DOI: 10.1097/00008571-200006000-00007] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 3.7] [Reference Citation Analysis]
208 Siever LJ, Koenigsberg HW, Harvey P, Mitropoulou V, Laruelle M, Abi-dargham A, Goodman M, Buchsbaum M. Cognitive and brain function in schizotypal personality disorder. Schizophrenia Research 2002;54:157-67. [DOI: 10.1016/s0920-9964(01)00363-2] [Cited by in Crossref: 114] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
209 Walker EF, Weinstein J, Baum K, Neumann CS. Antecedents of Schizophrenia: Moderating Effects of Development and Biological Sex. In: Häfner H, Gattaz WF, editors. Search for the Causes of Schizophrenia. Berlin: Springer Berlin Heidelberg; 1995. pp. 21-42. [DOI: 10.1007/978-3-642-79429-2_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
210 Michel FJ, Trudeau LE. Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture. Neuropharmacology 2000;39:1536-43. [PMID: 10854898 DOI: 10.1016/s0028-3908(99)00239-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
211 Li YC, Wang MJ, Gao WJ. Hyperdopaminergic modulation of inhibitory transmission is dependent on GSK-3β signaling-mediated trafficking of GABAA receptors. J Neurochem 2012;122:308-20. [PMID: 22676038 DOI: 10.1111/j.1471-4159.2012.07790.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
212 Nakazawa K, Zsiros V, Jiang Z, Nakao K, Kolata S, Zhang S, Belforte JE. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012;62:1574-83. [PMID: 21277876 DOI: 10.1016/j.neuropharm.2011.01.022] [Cited by in Crossref: 295] [Cited by in F6Publishing: 254] [Article Influence: 29.5] [Reference Citation Analysis]
213 Roberts SB, Hill CA, Dean B, Keks NA, Opeskin K, Copolov DL. Confirmation of the Diagnosis of Schizophrenia after Death Using DSM-IV: A Victorian Experience. Aust N Z J Psychiatry 1998;32:73-6. [DOI: 10.3109/00048679809062709] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 9.4] [Reference Citation Analysis]
214 Olsson H, Halldin C, Swahn C, Farde L. Quantification of [ 11 C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain. J Cereb Blood Flow Metab 1999;19:1164-73. [DOI: 10.1097/00004647-199910000-00013] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 21.6] [Reference Citation Analysis]
215 Eastwood SL, Story P, Burnet PWJ, Heath P, Harrison PJ. Differential changes in glutamate receptor subunit messenger RNAs in rat brain after haloperidol treatment. J Psychopharmacol 1994;8:196-203. [DOI: 10.1177/026988119400800402] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
216 Marcus MM, Jardemark K, Malmerfelt A, Gertow J, Konradsson-geuken Å, Svensson TH. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: Behavioral, biochemical, and electrophysiological evidence. Synapse 2012;66:277-90. [DOI: 10.1002/syn.21510] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
217 Gasnier M, Ellul P, Plaze M, Ahad PA. A New Look on an Old Issue: Comprehensive Review of Neurotransmitter Studies in Cerebrospinal Fluid of Patients with Schizophrenia and Antipsychotic Effect on Monoamine's Metabolism. Clin Psychopharmacol Neurosci 2021;19:395-410. [PMID: 34294610 DOI: 10.9758/cpn.2021.19.3.395] [Reference Citation Analysis]
218 Boyd A. Bromocriptine and psychosis: A literature review. Psych Quart 1995;66:87-95. [DOI: 10.1007/bf02238717] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
219 Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1081-90. [PMID: 14642968 DOI: 10.1016/j.pnpbp.2003.09.004] [Cited by in Crossref: 408] [Cited by in F6Publishing: 345] [Article Influence: 24.0] [Reference Citation Analysis]
220 Tanaka S. Dopaminergic control of working memory and its relevance to schizophrenia: A circuit dynamics perspective. Neuroscience 2006;139:153-71. [DOI: 10.1016/j.neuroscience.2005.08.070] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
221 Steinberg JL, Garver DL, Moeller FG, Raese JD, Orsulak PJ. Serum homovanillic acid levels in schizophrenic patients and normal control subjects. Psychiatry Research 1993;48:93-106. [DOI: 10.1016/0165-1781(93)90034-e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
222 Bitanihirwe BK, Weber L, Feldon J, Meyer U. Cognitive impairment following prenatal immune challenge in mice correlates with prefrontal cortical AKT1 deficiency. Int J Neuropsychopharmacol 2010;13:981-96. [PMID: 20219156 DOI: 10.1017/S1461145710000192] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
223 Strzelecki D, Podgórski M, Kałużyńska O, Gawlik-Kotelnicka O, Stefańczyk L, Kotlicka-Antczak M, Gmitrowicz A, Grzelak P. Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia. Nutrients 2015;7:8767-82. [PMID: 26506383 DOI: 10.3390/nu7105427] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
224 Li R, Guo W, Lei L, Zhang L, Liu Y, Han J, Chen L, Zhou B. Early-life exposure to the organophosphorus flame-retardant tris (1,3-dichloro-2-propyl) phosphate induces delayed neurotoxicity associated with DNA methylation in adult zebrafish. Environment International 2020;134:105293. [DOI: 10.1016/j.envint.2019.105293] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
225 Webber HE, Lopez-Gamundi P, Stamatovich SN, de Wit H, Wardle MC. Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adults. Neurosci Biobehav Rev 2021;120:123-58. [PMID: 33202256 DOI: 10.1016/j.neubiorev.2020.11.004] [Reference Citation Analysis]
226 Uzuneser TC, Schindehütte M, Dere E, von Hörsten S, Kornhuber J, Grömer TW, Müller CP. Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. European Neuropsychopharmacology 2018;28:1382-93. [DOI: 10.1016/j.euroneuro.2018.09.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
227 Hui L, Wu JQ, Ye MJ, Zheng K, He JC, Zhang X, Liu JH, Tian HJ, Gong BH, Chen DC, Lv MH, Soares JC, Zhang XY. Association of angiotensin-converting enzyme gene polymorphism with schizophrenia and depressive symptom severity in a Chinese population. Hum Psychopharmacol 2015;30:100-7. [PMID: 25694211 DOI: 10.1002/hup.2460] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
228 Xavier RM, Vorderstrasse A. Genetic Basis of Positive and Negative Symptom Domains in Schizophrenia. Biol Res Nurs 2017;19:559-75. [PMID: 28691507 DOI: 10.1177/1099800417715907] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
229 Searles S, Makarewicz JA, Dumas JA. The role of estradiol in schizophrenia diagnosis and symptoms in postmenopausal women. Schizophr Res 2018;196:35-8. [PMID: 28587815 DOI: 10.1016/j.schres.2017.05.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
230 Williams HJ, Owen MJ, O'Donovan MC. Is COMT a susceptibility gene for schizophrenia? Schizophr Bull 2007;33:635-41. [PMID: 17412710 DOI: 10.1093/schbul/sbm019] [Cited by in Crossref: 121] [Cited by in F6Publishing: 87] [Article Influence: 8.6] [Reference Citation Analysis]
231 Oyagi A, Hara H. Essential roles of heparin-binding epidermal growth factor-like growth factor in the brain. CNS Neurosci Ther 2012;18:803-10. [PMID: 23006514 DOI: 10.1111/j.1755-5949.2012.00371.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
232 Zhang JP, Robinson DG, Gallego JA, John M, Yu J, Addington J, Tohen M, Kane JM, Malhotra AK, Lencz T. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophr Bull 2015;41:1248-55. [PMID: 26320194 DOI: 10.1093/schbul/sbv116] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
233 Kritzer MF, Kohama SG. Ovarian hormones influence the morphology, distribution, and density of tyrosine hydroxylase immunoreactive axons in the dorsolateral prefrontal cortex of adult Rhesus monkeys. J Comp Neurol 1998;395:1-17. [DOI: 10.1002/(sici)1096-9861(19980525)395:1<1::aid-cne1>3.0.co;2-4] [Cited by in Crossref: 80] [Article Influence: 3.5] [Reference Citation Analysis]
234 Leung C, Jia Z. Mouse Genetic Models of Human Brain Disorders. Front Genet 2016;7:40. [PMID: 27047540 DOI: 10.3389/fgene.2016.00040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
235 Chapman CAR, Goshi N, Seker E. Multifunctional Neural Interfaces for Closed‐Loop Control of Neural Activity. Adv Funct Mater 2018;28:1703523. [DOI: 10.1002/adfm.201703523] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
236 Bardgett ME, Csernansky JG. Antipsychotic Drug Action After Lesions to the Hippocampus or Frontal Cortex. In: Csernansky JG, editor. Antipsychotics. Berlin: Springer Berlin Heidelberg; 1996. pp. 267-88. [DOI: 10.1007/978-3-642-61007-3_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
237 Marazziti D, Baroni S, Masala I, Giannaccini G, Betti L, Palego L, Dell’osso MC, Consoli G, Castagna M, Lucacchini A. [3H]-YM-09151-2 binding sites in human brain postmortem. Neurochemistry International 2009;55:643-7. [DOI: 10.1016/j.neuint.2009.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
238 Stępnicki P, Kondej M, Kaczor AA. Current Concepts and Treatments of Schizophrenia. Molecules 2018;23:E2087. [PMID: 30127324 DOI: 10.3390/molecules23082087] [Cited by in Crossref: 72] [Cited by in F6Publishing: 36] [Article Influence: 24.0] [Reference Citation Analysis]
239 Babić Leko M, Hof PR, Šimić G. Alterations and interactions of subcortical modulatory systems in Alzheimer's disease. Prog Brain Res 2021;261:379-421. [PMID: 33785136 DOI: 10.1016/bs.pbr.2020.07.016] [Reference Citation Analysis]
240 Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. Progress in Neurobiology 2005;75:275-93. [DOI: 10.1016/j.pneurobio.2005.03.002] [Cited by in Crossref: 260] [Cited by in F6Publishing: 207] [Article Influence: 16.3] [Reference Citation Analysis]
241 Wang Q, Jolly JP, Surmeier JD, Mullah BM, Lidow MS, Bergson CM, Robishaw JD. Differential dependence of the D1 and D5 dopamine receptors on the G protein gamma 7 subunit for activation of adenylylcyclase. J Biol Chem 2001;276:39386-93. [PMID: 11500503 DOI: 10.1074/jbc.M104981200] [Cited by in Crossref: 44] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
242 Goodman MS, Bridgman AC, Rabin RA, Blumberger DM, Rajji TK, Daskalakis ZJ, George TP, Barr MS. Differential effects of cannabis dependence on cortical inhibition in patients with schizophrenia and non-psychiatric controls. Brain Stimul 2017;10:275-82. [PMID: 27964871 DOI: 10.1016/j.brs.2016.11.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
243 Spitzer M, Beuckers J, Beyer S, Maier S, Hermle L. Contextual Insensitivity in Thought-Disordered Schizophrenic Patients: Evidence from Pauses in Spontaneous Speech. Lang Speech 1994;37:171-85. [DOI: 10.1177/002383099403700205] [Cited by in Crossref: 41] [Cited by in F6Publishing: 13] [Article Influence: 8.2] [Reference Citation Analysis]
244 Walker EF, Diforio D, Baum K. Developmental neuropathology and the precursors of schizophrenia. Acta Psychiatr Scand 1999;99:12-9. [DOI: 10.1111/j.1600-0447.1999.tb05978.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
245 Kondo T, Mihara K, Suzuki A, Yasui-furukori N, Kaneko S. Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003;27:921-6. [DOI: 10.1016/s0278-5846(03)00151-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
246 Jo YS, Lee J, Mizumori SJ. Effects of prefrontal cortical inactivation on neural activity in the ventral tegmental area. J Neurosci 2013;33:8159-71. [PMID: 23658156 DOI: 10.1523/JNEUROSCI.0118-13.2013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
247 Tzschentke T. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Progress in Neurobiology 2001;63:241-320. [DOI: 10.1016/s0301-0082(00)00033-2] [Cited by in Crossref: 311] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
248 Sun H, Wang F, Fan H, Yan Q, Cui K, Yuan W, Zhao F, Zhao L, Yuan J, Yang F, Kosten TR, Zhang XY. The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients. PLoS One 2013;8:e70963. [PMID: 23951054 DOI: 10.1371/journal.pone.0070963] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
249 van Winkel R, Stefanis NC, Myin-Germeys I. Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull 2008;34:1095-105. [PMID: 18718885 DOI: 10.1093/schbul/sbn101] [Cited by in Crossref: 299] [Cited by in F6Publishing: 229] [Article Influence: 23.0] [Reference Citation Analysis]
250 Snyder GL, Vanover KE. PDE Inhibitors for the Treatment of Schizophrenia. In: Zhang H, Xu Y, O'donnell JM, editors. Phosphodiesterases: CNS Functions and Diseases. Cham: Springer International Publishing; 2017. pp. 385-409. [DOI: 10.1007/978-3-319-58811-7_14] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
251 Lacroix LP, Hows MEP, Shah AJ, Hagan JJ, Heidbreder CA. Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex. Neuropsychopharmacol 2003;28:839-49. [DOI: 10.1038/sj.npp.1300114] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 3.6] [Reference Citation Analysis]
252 Shonberg J, Draper-Joyce C, Mistry SN, Christopoulos A, Scammells PJ, Lane JR, Capuano B. Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor. J Med Chem 2015;58:5287-307. [PMID: 26052807 DOI: 10.1021/acs.jmedchem.5b00581] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
253 Molero P, Ortuño F, Zalacain M, Patiño-García A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 2007;7:418-26. [PMID: 17363961 DOI: 10.1038/sj.tpj.6500441] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
254 El-Khodor BF, Boksa P. Birth insult increases amphetamine-induced behavioral responses in the adult rat. Neuroscience 1998;87:893-904. [PMID: 9759977 DOI: 10.1016/s0306-4522(98)00194-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
255 Kubota M, Nagashima T, Takano H, Kodaka F, Fujiwara H, Takahata K, Moriguchi S, Kimura Y, Higuchi M, Okubo Y, Takahashi H, Ito H, Suhara T. Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia. Int J Neuropsychopharmacol. 2017;20:928-935. [PMID: 29016872 DOI: 10.1093/ijnp/pyx063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
256 Toro MG, Ruiz JS, Talavera JA, Blanco C. Chaos theories and therapeutic commonalities among depression, Parkinson's disease, and cardiac arrhythmias. Comprehensive Psychiatry 1999;40:238-44. [DOI: 10.1016/s0010-440x(99)90011-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Swerdlow NR, Lipska BK, Weinberger DR, Braff DL, Jaskiw GE, Geyer MA. Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology (Berl) 1995;122:27-34. [PMID: 8711061 DOI: 10.1007/BF02246438] [Cited by in Crossref: 124] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
258 Korth C. Aggregated proteins in schizophrenia and other chronic mental diseases: DISC1opathies. Prion 2012;6:134-41. [PMID: 22421208 DOI: 10.4161/pri.18989] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
259 Weichert D, Banerjee A, Hiller C, Kling RC, Hübner H, Gmeiner P. Molecular Determinants of Biased Agonism at the Dopamine D 2 Receptor. J Med Chem 2015;58:2703-17. [DOI: 10.1021/jm501889t] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
260 Ko CY, Liu YP. Disruptions of sensorimotor gating, cytokines, glycemia, monoamines, and genes in both sexes of rats reared in social isolation can be ameliorated by oral chronic quetiapine administration. Brain Behav Immun 2016;51:119-30. [PMID: 26254231 DOI: 10.1016/j.bbi.2015.08.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
261 Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 1997;17:8528-35. [PMID: 9334425 [PMID: 9334425 DOI: 10.1523/jneurosci.17-21-08528.1997] [Cited by in Crossref: 518] [Article Influence: 21.6] [Reference Citation Analysis]
262 Cohen SM, Tsien RW, Goff DC, Halassa MM. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res. 2015;Jan 9; Epub ahead of print. [PMID: 25583246 DOI: 10.1016/j.schres.2014.12.026] [Cited by in Crossref: 125] [Cited by in F6Publishing: 92] [Article Influence: 20.8] [Reference Citation Analysis]
263 Brisch R, Bielau H, Saniotis A, Wolf R, Bogerts B, Krell D, Steiner J, Braun K, Krzyżanowska M, Krzyżanowski M, Jankowski Z, Kaliszan M, Bernstein HG, Gos T. Calretinin and parvalbumin in schizophrenia and affective disorders: a mini-review, a perspective on the evolutionary role of calretinin in schizophrenia, and a preliminary post-mortem study of calretinin in the septal nuclei. Front Cell Neurosci 2015;9:393. [PMID: 26578879 DOI: 10.3389/fncel.2015.00393] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
264 Kischka U, Kammer T, Maier S, Weisbrod M, Thimm M, Spitzer M. Dopaminergic modulation of semantic network activation. Neuropsychologia 1996;34:1107-13. [DOI: 10.1016/0028-3932(96)00024-3] [Cited by in Crossref: 98] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
265 Javanbakht A. Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia. Med Hypotheses 2006;67:1173-84. [PMID: 16824690 DOI: 10.1016/j.mehy.2006.03.054] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
266 Haybaeck J, Postruznik M, Miller CL, Dulay JR, Llenos IC, Weis S. Increased expression of retinoic acid-induced gene 1 in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Neuropsychiatr Dis Treat 2015;11:279-89. [PMID: 25678793 DOI: 10.2147/NDT.S72536] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
267 Hills TT. Animal foraging and the evolution of goal-directed cognition. Cogn Sci 2006;30:3-41. [PMID: 21702807 DOI: 10.1207/s15516709cog0000_50] [Cited by in Crossref: 137] [Cited by in F6Publishing: 58] [Article Influence: 15.2] [Reference Citation Analysis]
268 Samaha AN. Can antipsychotic treatment contribute to drug addiction in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2014;52:9-16. [PMID: 23793001 DOI: 10.1016/j.pnpbp.2013.06.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
269 Amato D, Kruyer A, Samaha AN, Heinz A. Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. Front Psychiatry 2019;10:314. [PMID: 31214054 DOI: 10.3389/fpsyt.2019.00314] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
270 Stachowiak MK, Kucinski A, Curl R, Syposs C, Yang Y, Narla S, Terranova C, Prokop D, Klejbor I, Bencherif M, Birkaya B, Corso T, Parikh A, Tzanakakis ES, Wersinger S, Stachowiak EK. Schizophrenia: a neurodevelopmental disorder--integrative genomic hypothesis and therapeutic implications from a transgenic mouse model. Schizophr Res 2013;143:367-76. [PMID: 23231877 DOI: 10.1016/j.schres.2012.11.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
271 Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav 2011;99:245-53. [PMID: 21115035 DOI: 10.1016/j.pbb.2010.11.009] [Cited by in Crossref: 109] [Cited by in F6Publishing: 83] [Article Influence: 9.9] [Reference Citation Analysis]
272 Veronese M, Santangelo B, Jauhar S, D'Ambrosio E, Demjaha A, Salimbeni H, Huajie J, McCrone P, Turkheimer F, Howes O. A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach. Neuropsychopharmacology 2021;46:1122-32. [PMID: 32961543 DOI: 10.1038/s41386-020-00866-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
273 Talkowski ME, Bamne M, Mansour H, Nimgaonkar VL. Dopamine genes and schizophrenia: case closed or evidence pending? Schizophr Bull 2007;33:1071-81. [PMID: 17630406 DOI: 10.1093/schbul/sbm076] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
274 Hartman DS, Civelli O. Molecular attributes of dopamine receptors: new potential for antipsychotic drug development. Ann Med 1996;28:211-9. [PMID: 8811164 DOI: 10.3109/07853899609033122] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
275 Alpár A, Di Marzo V, Harkany T. At the Tip of an Iceberg: Prenatal Marijuana and Its Possible Relation to Neuropsychiatric Outcome in the Offspring. Biol Psychiatry 2016;79:e33-45. [PMID: 26549491 DOI: 10.1016/j.biopsych.2015.09.009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 7.7] [Reference Citation Analysis]
276 Bloem BR, Beckley DJ, van Vugt JP, van Dijk JG, Remler MP, Langston JW, Roos RA. Long latency postural reflexes are under supraspinal dopaminergic control. Mov Disord 1995;10:580-8. [PMID: 8552109 DOI: 10.1002/mds.870100509] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
277 Wurfel BE, Drevets WC, Bliss SA, McMillin JR, Suzuki H, Ford BN, Morris HM, Teague TK, Dantzer R, Savitz JB. Serum kynurenic acid is reduced in affective psychosis. Transl Psychiatry 2017;7:e1115. [PMID: 28463241 DOI: 10.1038/tp.2017.88] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
278 Mané A, Gallego J, Lomeña F, Mateos JJ, Fernandez-Egea E, Horga G, Cot A, Pavia J, Bernardo M, Parellada E. A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients. Psychiatry Res 2011;194:79-84. [PMID: 21831607 DOI: 10.1016/j.pscychresns.2011.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
279 Ballmaier M, Zoli M, Leo G, Agnati LF, Spano P. Preferential alterations in the mesolimbic dopamine pathway of heterozygous reeler mice: an emerging animal-based model of schizophrenia. Eur J Neurosci 2002;15:1197-205. [PMID: 11982630 DOI: 10.1046/j.1460-9568.2002.01952.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
280 Vink M, de Leeuw M, Pouwels R, van den Munkhof HE, Kahn RS, Hillegers M. Diminishing striatal activation across adolescent development during reward anticipation in offspring of schizophrenia patients. Schizophr Res 2016;170:73-9. [PMID: 26631365 DOI: 10.1016/j.schres.2015.11.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
281 Bonoldi I, Howes O. The Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia. A New Era of Catecholamines in the Laboratory and Clinic. Elsevier; 2013. pp. 199-220. [DOI: 10.1016/b978-0-12-411512-5.00010-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
282 Sokoloff P, Le Foll B, Herman J. The dopamine D3 receptor, a quarter century later. Eur J Neurosci 2017;45:2-19. [DOI: 10.1111/ejn.13390] [Cited by in Crossref: 117] [Cited by in F6Publishing: 85] [Article Influence: 23.4] [Reference Citation Analysis]
283 Heidbreder CA, Groenewegen HJ. The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics. Neuroscience & Biobehavioral Reviews 2003;27:555-79. [DOI: 10.1016/j.neubiorev.2003.09.003] [Cited by in Crossref: 523] [Cited by in F6Publishing: 498] [Article Influence: 29.1] [Reference Citation Analysis]
284 Keshavan MS, Lawler AN, Nasrallah HA, Tandon R. New drug developments in psychosis: Challenges, opportunities and strategies. Prog Neurobiol 2017;152:3-20. [PMID: 27519538 DOI: 10.1016/j.pneurobio.2016.07.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
285 Corbett R, Hartman H, Kerman L, Woods A, Strupczewski J, Helsley G, Conway P, Dunn R. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacology Biochemistry and Behavior 1993;45:9-17. [DOI: 10.1016/0091-3057(93)90079-9] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 3.6] [Reference Citation Analysis]
286 Niijima-Yaoita F, Tsuchiya M, Saito H, Nagasawa Y, Murai S, Arai Y, Nakagawasai O, Nemoto W, Tadano T, Tan-No K. Influence of a long-term powdered diet on the social interaction test and dopaminergic systems in mice. Neurochem Int 2013;63:309-15. [PMID: 23871718 DOI: 10.1016/j.neuint.2013.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
287 Ginovart N, Tournier BB, Moulin-Sallanon M, Steimer T, Ibanez V, Millet P. Chronic Δ⁹-tetrahydrocannabinol exposure induces a sensitization of dopamine D₂/₃ receptors in the mesoaccumbens and nigrostriatal systems. Neuropsychopharmacology 2012;37:2355-67. [PMID: 22692568 DOI: 10.1038/npp.2012.91] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
288 Klejbor I, Myers JM, Hausknecht K, Corso TD, Gambino AS, Morys J, Maher PA, Hard R, Richards J, Stachowiak EK, Stachowiak MK. Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice. J Neurochem 2006;97:1243-58. [DOI: 10.1111/j.1471-4159.2006.03754.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 3.5] [Reference Citation Analysis]
289 Kahn R, Siever LJ, Gabriel S, Amin F, Stern RG, Dumont K, Apter S, Davidson M. Serotonin function in schizophrenia: Effects of meta- chlorophenylpiperazine in schizophrenia patients and healthy subjects. Psychiatry Research 1992;43:1-12. [DOI: 10.1016/0165-1781(92)90136-q] [Cited by in Crossref: 42] [Article Influence: 1.4] [Reference Citation Analysis]
290 Zhang H, Ozbay F, Lappalainen J, Kranzler HR, van Dyck CH, Charney DS, Price LH, Southwick S, Yang BZ, Rasmussen A. Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer’s disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:387-393. [PMID: 16649215 DOI: 10.1002/ajmg.b.30332] [Cited by in Crossref: 131] [Cited by in F6Publishing: 118] [Article Influence: 8.7] [Reference Citation Analysis]
291 Frånberg O, Marcus MM, Svensson TH. Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse 2012;66:650-60. [DOI: 10.1002/syn.21551] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
292 Weiner I, Joel D. Dopamine in Schizophrenia Dysfunctional Information Processing in Basal Ganglia — Thalamocortical Split Circuits. In: Di Chiara G, editor. Dopamine in the CNS II. Berlin: Springer Berlin Heidelberg; 2002. pp. 417-71. [DOI: 10.1007/978-3-662-06765-9_13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
293 Cattapan-ludewig K, Ludewig S, Jaquenoud Sirot E, Etzensberger M, Hasler F. Warum rauchen Schizophreniepatienten? Nervenarzt 2005;76:287-94. [DOI: 10.1007/s00115-004-1818-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
294 Sharma AN, Elased KM, Lucot JB. Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice. J Psychopharmacol 2012;26:724-32. [PMID: 22331176 DOI: 10.1177/0269881111434620] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
295 Wang A, Shi W, Huang J, Yan Y. Adaptive soft molecular self-assemblies. Soft Matter 2016;12:337-57. [DOI: 10.1039/c5sm02397a] [Cited by in Crossref: 114] [Cited by in F6Publishing: 7] [Article Influence: 22.8] [Reference Citation Analysis]
296 Mohr C, Krummenacher P, Landis T, Sandor PS, Fathi M, Brugger P. Psychometric schizotypy modulates levodopa effects on lateralized lexical decision performance. Journal of Psychiatric Research 2005;39:241-50. [DOI: 10.1016/j.jpsychires.2004.08.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
297 Möller H. Viewpoint: Methodological Issues in Psychiatry: Psychiatry as an Empirical Science. The World Journal of Biological Psychiatry 2009;2:38-47. [DOI: 10.3109/15622970109039983] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
298 Ben-Shachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J Neural Transm (Vienna). 2009;116:1383-1396. [PMID: 19784753 DOI: 10.1007/s00702-009-0319-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
299 Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704. [PMID: 31299229 DOI: 10.1016/j.neuropharm.2019.107704] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 23.5] [Reference Citation Analysis]
300 Port RL, Seybold KS. Hippocampal synaptic plasticity as a biological substrate underlying episodic psychosis. Biological Psychiatry 1995;37:318-24. [DOI: 10.1016/0006-3223(94)00128-p] [Cited by in Crossref: 19] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
301 de Leeuw M, Bohlken MM, Mandl RC, Kahn RS, Vink M. Reduced fronto-striatal white matter integrity in schizophrenia patients and unaffected siblings: a DTI study. NPJ Schizophr 2015;1:15001. [PMID: 27336028 DOI: 10.1038/npjschz.2015.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
302 Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry 2002;51:349-57. [DOI: 10.1016/s0006-3223(01)01342-7] [Cited by in Crossref: 127] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
303 Yoon JH, Sheremata SL, Rokem A, Silver MA. Windows to the soul: vision science as a tool for studying biological mechanisms of information processing deficits in schizophrenia. Front Psychol 2013;4:681. [PMID: 24198792 DOI: 10.3389/fpsyg.2013.00681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
304 George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophrenia Research 2007;93:42-50. [DOI: 10.1016/j.schres.2007.03.011] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
305 Peled A, Geva AB. The Perception of Rorschach Inkblots in Schizophrenia: a Neural Network Model. International Journal of Neuroscience 2009;104:49-61. [DOI: 10.3109/00207450009035008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
306 Thacker SK, Perna MK, Ward JJ, Schaefer TL, Williams MT, Kostrzewa RM, Brown RW. The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. European Journal of Neuroscience 2006;24:2075-83. [DOI: 10.1111/j.1460-9568.2006.05048.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
307 Siris SG. Assessment and Treatment of Depression in Schizophrenia. Psychiatric Annals 1994;24:463-7. [DOI: 10.3928/0048-5713-19940901-07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
308 de Castro-Catala M, Barrantes-Vidal N, Sheinbaum T, Moreno-Fortuny A, Kwapil TR, Rosa A. COMT-by-sex interaction effect on psychosis proneness. Biomed Res Int 2015;2015:829237. [PMID: 25722988 DOI: 10.1155/2015/829237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
309 Yoshikawa A, Li J, Meltzer HY. A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs. Pharmacogenomics J 2020;20:260-70. [PMID: 31636356 DOI: 10.1038/s41397-019-0101-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
310 Yan Z, Song W, Surmeier DJ. D 2 Dopamine Receptors Reduce N-Type Ca 2+ Currents in Rat Neostriatal Cholinergic Interneurons Through a Membrane-Delimited, Protein-Kinase-C-Insensitive Pathway. Journal of Neurophysiology 1997;77:1003-15. [DOI: 10.1152/jn.1997.77.2.1003] [Cited by in Crossref: 170] [Cited by in F6Publishing: 176] [Article Influence: 7.1] [Reference Citation Analysis]
311 Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol 2012;:167-210. [PMID: 23027416 DOI: 10.1007/978-3-642-25758-2_7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 7.9] [Reference Citation Analysis]
312 Frankle WG, Laruelle M. Neuroreceptor imaging in psychiatric disorders. Ann Nucl Med 2002;16:437-46. [PMID: 12508833 DOI: 10.1007/BF02988639] [Cited by in Crossref: 38] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
313 Kabbaj M, Akil H. Individual differences in novelty-seeking behavior in rats: a c-fos study. Neuroscience 2001;106:535-45. [PMID: 11591454 DOI: 10.1016/s0306-4522(01)00291-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
314 Varga TG, de Toledo Simões JG, Siena A, Henrique E, da Silva RCB, Dos Santos Bioni V, Ramos AC, Rosenstock TR. Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats. Psychopharmacology (Berl) 2021;238:2569-85. [PMID: 34089344 DOI: 10.1007/s00213-021-05880-1] [Reference Citation Analysis]
315 Brake WG, Sullivan RM, Gratton A. Perinatal distress leads to lateralized medial prefrontal cortical dopamine hypofunction in adult rats. J Neurosci 2000;20:5538-43. [PMID: 10884337 [PMID: 10884337 DOI: 10.1523/jneurosci.20-14-05538.2000] [Cited by in Crossref: 84] [Article Influence: 4.0] [Reference Citation Analysis]
316 Byne W, White L, Parella M, Adams R, Harvey PD, Davis KL. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. Int J Geriat Psychiatry 1998;13:473-9. [DOI: 10.1002/(sici)1099-1166(199807)13:7<473::aid-gps800>3.0.co;2-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
317 Tarazi FI, Baldessarini RJ. Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions. J Neurosci Res 1999;55:401-10. [DOI: 10.1002/(sici)1097-4547(19990215)55:4<401::aid-jnr1>3.0.co;2-h] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
318 Darvesh AS, Carroll RT, Geldenhuys WJ, Gudelsky GA, Klein J, Meshul CK, Van der Schyf CJ. In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery. Expert Opin Drug Discov 2011;6:109-27. [PMID: 21532928 DOI: 10.1517/17460441.2011.547189] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
319 Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 1997;17:8147-55. [PMID: 9334390 [PMID: 9334390 DOI: 10.1523/jneurosci.17-21-08147.1997] [Cited by in Crossref: 269] [Article Influence: 11.2] [Reference Citation Analysis]
320 Liu W, Wang D, Hong W, Yu Y, Tang J, Wang J, Liu F, Xu X, Tan L, Chen X. Psychotomimetic effects of different doses of MK-801 and the underlying mechanisms in a selective memory impairment model. Behavioural Brain Research 2017;320:517-25. [DOI: 10.1016/j.bbr.2016.10.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
321 Nishi A, Snyder GL, Fienberg AA, Fisone G, Aperia A, Nairn AC, Greengard P. Requirement for DARPP-32 in mediating effect of dopamine D2 receptor activation. Eur J Neurosci 1999;11:2589-92. [PMID: 10383649 DOI: 10.1046/j.1460-9568.1999.00724.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
322 Kim T, Kim HJ, Park JK, Kim JW, Chung JH. Association between polymorphisms of arachidonate 12-lipoxygenase (ALOX12) and schizophrenia in a Korean population. Behav Brain Funct 2010;6:44. [PMID: 20626912 DOI: 10.1186/1744-9081-6-44] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
323 Dubol M, Trichard C, Leroy C, Sandu AL, Rahim M, Granger B, Tzavara ET, Karila L, Martinot JL, Artiges E. Dopamine Transporter and Reward Anticipation in a Dimensional Perspective: A Multimodal Brain Imaging Study. Neuropsychopharmacology 2018;43:820-7. [PMID: 28829051 DOI: 10.1038/npp.2017.183] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
324 Pickar D. Prospects for pharmacotherapy of schizophrenia. The Lancet 1995;345:557-62. [DOI: 10.1016/s0140-6736(95)90469-7] [Cited by in Crossref: 71] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
325 Tsukada H, Miyasato K, Nishiyama S, Fukumoto D, Kakiuchi T, Domino EF. Nicotine Normalizes Increased Prefrontal Cortical Dopamine D1 Receptor Binding and Decreased Working Memory Performance Produced by Repeated Pretreatment with MK-801: A PET Study in Conscious Monkeys. Neuropsychopharmacol 2005;30:2144-53. [DOI: 10.1038/sj.npp.1300745] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
326 Apud JA, Weinberger DR. Treatment of Cognitive Deficits Associated with Schizophrenia: Potential Role of Catechol-O-Methyltransferase Inhibitors. CNS Drugs 2007;21:535-57. [DOI: 10.2165/00023210-200721070-00002] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
327 Austin M, Mitchell P. The anatomy of melancholia: does frontal-subcortical pathophysiology underpin its psychomotor and cognitive manifestations? Psychol Med 1995;25:665-72. [DOI: 10.1017/s0033291700034929] [Cited by in Crossref: 38] [Article Influence: 3.2] [Reference Citation Analysis]
328 Taylor N, Hollis JP, Corcoran S, Gross R, Cuthbert B, Swails LW, Duncan E. Impaired reward responsiveness in schizophrenia. Schizophr Res 2018;199:46-52. [PMID: 29526451 DOI: 10.1016/j.schres.2018.02.057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
329 Wolkin A, Duncan E, Sanfilipo M, Wieland S, Cooper TB, Rotrosen J. Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function. J Neural Transm Gen Sect 1994;95:49-61. [PMID: 7857586 DOI: 10.1007/BF01283030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
330 Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO. Treatment of Negative Symptoms in Schizophrenia and Schizoaffective Disorder by Selegiline Augmentation of Antipsychotic Medication: A Pilot Study Examining the Role of Dopamine. The Journal of Nervous and Mental Disease 1996;184:295-301. [DOI: 10.1097/00005053-199605000-00005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
331 Rodvelt KR, Schachtman TR, Kracke GR, Miller DK. NMDA receptor blockade augmented nicotine-evoked dopamine release from rat prefrontal cortex slices. Neurosci Lett 2008;440:319-22. [PMID: 18579301 DOI: 10.1016/j.neulet.2008.05.106] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
332 Labrie V, Roder JC. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev 2010;34:351-72. [PMID: 19695284 DOI: 10.1016/j.neubiorev.2009.08.002] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 7.4] [Reference Citation Analysis]
333 O'connor WT, O'shea SD. Clozapine and GABA transmission in schizophrenia disease models. Pharmacology & Therapeutics 2015;150:47-80. [DOI: 10.1016/j.pharmthera.2015.01.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
334 Lavigne F, Darmon N. Dopaminergic neuromodulation of semantic priming in a cortical network model. Neuropsychologia 2008;46:3074-87. [DOI: 10.1016/j.neuropsychologia.2008.06.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
335 Chan NK, Kim J, Shah P, Brown EE, Plitman E, Carravaggio F, Iwata Y, Gerretsen P, Graff-guerrero A. Resting-state functional connectivity in treatment response and resistance in schizophrenia: A systematic review. Schizophrenia Research 2019;211:10-20. [DOI: 10.1016/j.schres.2019.07.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
336 Chen KC, Lee IH, Yeh TL, Chiu NT, Chen PS, Yang YK, Lu RB, Chen CC. Schizotypy trait and striatal dopamine receptors in healthy volunteers. Psychiatry Res 2012;201:218-21. [PMID: 22429746 DOI: 10.1016/j.pscychresns.2011.07.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
337 Zierhut KC, Schulte-Kemna A, Kaufmann J, Steiner J, Bogerts B, Schiltz K. Distinct structural alterations independently contributing to working memory deficits and symptomatology in paranoid schizophrenia. Cortex 2013;49:1063-72. [PMID: 23040316 DOI: 10.1016/j.cortex.2012.08.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
338 Yang CR, Chen L. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment. Neuroscientist 2005;11:452-70. [PMID: 16151046 DOI: 10.1177/1073858405279692] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
339 Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci 2015;69:243-58. [PMID: 25296946 DOI: 10.1111/pcn.12242] [Cited by in Crossref: 96] [Cited by in F6Publishing: 58] [Article Influence: 13.7] [Reference Citation Analysis]
340 Tabor A, Weisenburger S, Banerjee A, Purkayastha N, Kaindl JM, Hübner H, Wei L, Grömer TW, Kornhuber J, Tschammer N, Birdsall NJ, Mashanov GI, Sandoghdar V, Gmeiner P. Visualization and ligand-induced modulation of dopamine receptor dimerization at the single molecule level. Sci Rep 2016;6:33233. [PMID: 27615810 DOI: 10.1038/srep33233] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
341 Petkova-Kirova P, Rakovska A, Zaekova G, Ballini C, Corte LD, Radomirov R, Vágvölgyi A. Stimulation by neurotensin of dopamine and 5-hydroxytryptamine (5-HT) release from rat prefrontal cortex: possible role of NTR1 receptors in neuropsychiatric disorders. Neurochem Int 2008;53:355-61. [PMID: 18835308 DOI: 10.1016/j.neuint.2008.08.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
342 Wengler K, He X, Abi-Dargham A, Horga G. Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. Neuroimage 2020;208:116457. [PMID: 31841683 DOI: 10.1016/j.neuroimage.2019.116457] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
343 Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res 1993;46:139-49. [PMID: 8483973 DOI: 10.1016/0165-1781(93)90016-a] [Cited by in Crossref: 47] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
344 Slaghuis WL, Thompson AK. The effect of peripheral visual motion on focal contrast sensitivity in positive- and negative-symptom schizophrenia. Neuropsychologia 2003;41:968-80. [PMID: 12667532 DOI: 10.1016/s0028-3932(02)00321-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
345 Peeters MM, van Grinsven B, Foster CW, Cleij TJ, Banks CE. Introducing Thermal Wave Transport Analysis (TWTA): A Thermal Technique for Dopamine Detection by Screen-Printed Electrodes Functionalized with Molecularly Imprinted Polymer (MIP) Particles. Molecules 2016;21:E552. [PMID: 27128891 DOI: 10.3390/molecules21050552] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
346 Suzuki M, Hurd YL, Sokoloff P, Schwartz J, Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Research 1998;779:58-74. [DOI: 10.1016/s0006-8993(97)01078-0] [Cited by in Crossref: 149] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
347 Mohr C, Ettinger U. An Overview of the Association between Schizotypy and Dopamine. Front Psychiatry 2014;5:184. [PMID: 25566103 DOI: 10.3389/fpsyt.2014.00184] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
348 Elsworth JD, Groman SM, Jentsch JD, Leranth C, Redmond DE Jr, Kim JD, Diano S, Roth RH. Primate phencyclidine model of schizophrenia: sex-specific effects on cognition, brain derived neurotrophic factor, spine synapses, and dopamine turnover in prefrontal cortex. Int J Neuropsychopharmacol 2014;18:pyu048. [PMID: 25522392 DOI: 10.1093/ijnp/pyu048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
349 Rice MW, Roberts RC, Melendez-Ferro M, Perez-Costas E. Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia. Brain Struct Funct 2016;221:185-201. [PMID: 25269834 DOI: 10.1007/s00429-014-0901-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
350 Heidbreder CA, Lacroix L, Atkins AR, Organ AJ, Murray S, West A, Shah AJ. Development and application of a sensitive high performance ion-exchange chromatography method for the simultaneous measurement of dopamine, 5-hydroxytryptamine and norepinephrine in microdialysates from the rat brain. Journal of Neuroscience Methods 2001;112:135-44. [DOI: 10.1016/s0165-0270(01)00460-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
351 Kolachana B, Saunders R, Weinberger D. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: Anin vivo neurochemical assessment in the rhesus monkey. Neuroscience 1995;69:859-68. [DOI: 10.1016/0306-4522(95)00246-f] [Cited by in Crossref: 61] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
352 Bourrain S, Collins I, Neduvelil JG, Rowley M, Leeson PD, Patel S, Patel S, Emms F, Marwood R, Chapman KL, Fletcher AE, Showell GA. Substituted pyrazoles as novel selective ligands for the human dopamine D 4 receptor. Bioorganic & Medicinal Chemistry 1998;6:1731-43. [DOI: 10.1016/s0968-0896(98)00134-5] [Cited by in Crossref: 13] [Article Influence: 0.6] [Reference Citation Analysis]
353 Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000;97:8104-9. [PMID: 10884434 DOI: 10.1073/pnas.97.14.8104] [Cited by in Crossref: 664] [Cited by in F6Publishing: 559] [Article Influence: 31.6] [Reference Citation Analysis]
354 Ryoo HL, Joyce JN. Loss of dopamine D2 receptors varies along the rostrocaudal axis of the hippocampal complex in alzheimer's disease. J Comp Neurol 1994;348:94-110. [DOI: 10.1002/cne.903480105] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
355 Akil M, Lewis DA. The distribution of tyrosine hydroxylase-immunoreactive fibers in the human entorhinal cortex. Neuroscience 1994;60:857-74. [PMID: 7936208 DOI: 10.1016/0306-4522(94)90268-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.2] [Reference Citation Analysis]
356 Chertkow Y, Weinreb O, Youdim MB, Silver H. Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. J Neural Transm (Vienna) 2007;114:1443-54. [PMID: 17576515 DOI: 10.1007/s00702-007-0753-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
357 Wen Z, Christian KM, Song H, Ming GL. Modeling psychiatric disorders with patient-derived iPSCs. Curr Opin Neurobiol 2016;36:118-27. [PMID: 26705693 DOI: 10.1016/j.conb.2015.11.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
358 Corbett R, Griffiths L, Shipley JE, Shukla U, Strupczewski JT, Szczepanik AM, Szewczak MR, Turk DJ, Vargas HM, Kongsamut S; the Iloperidone Project Team. Iloperidone: Preclinical Profile and Early Clinical Evaluation. CNS Drug Reviews 1997;3:120-47. [DOI: 10.1111/j.1527-3458.1997.tb00320.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
359 Gemperle A, Enz A, Pozza M, Lthi A, Olpe H. Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study. Neuroscience 2003;117:681-95. [DOI: 10.1016/s0306-4522(02)00769-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
360 Chen W, Lin Y, Chang Y, Chang K, Hsia Y. Forced degradation behavior of epidepride and development of a stability-indicating method based on liquid chromatography–mass spectrometry. Journal of Food and Drug Analysis 2014;22:248-56. [DOI: 10.1016/j.jfda.2013.09.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
361 Remington G, Agid O, Foussias G. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Rev Neurother 2011;11:589-607. [PMID: 21469931 DOI: 10.1586/ern.10.191] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
362 Brake WG, Noel MB, Boksa P, Gratton A. Influence of perinatal factors on the nucleus accumbens dopamine response to repeated stress during adulthood: an electrochemical study in the rat. Neuroscience 1997;77:1067-76. [PMID: 9130788 DOI: 10.1016/s0306-4522(96)00543-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
363 Zandbelt BB, van Buuren M, Kahn RS, Vink M. Reduced proactive inhibition in schizophrenia is related to corticostriatal dysfunction and poor working memory. Biol Psychiatry 2011;70:1151-8. [PMID: 21903198 DOI: 10.1016/j.biopsych.2011.07.028] [Cited by in Crossref: 91] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
364 Komatsu H, Fukuchi M, Habata Y. Potential Utility of Biased GPCR Signaling for Treatment of Psychiatric Disorders. Int J Mol Sci 2019;20:E3207. [PMID: 31261897 DOI: 10.3390/ijms20133207] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
365 Takeuchi Y, Nagy AJ, Barcsai L, Li Q, Ohsawa M, Mizuseki K, Berényi A. The Medial Septum as a Potential Target for Treating Brain Disorders Associated With Oscillopathies. Front Neural Circuits 2021;15:701080. [PMID: 34305537 DOI: 10.3389/fncir.2021.701080] [Reference Citation Analysis]
366 Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R. Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol 2013;386:107-24. [PMID: 23001156 DOI: 10.1007/s00210-012-0797-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
367 Turgeon S, Roche J. The delayed effects of phencyclidine enhance amphetamine-induced behavior and striatal c-Fos expression in the rat. Neuroscience 1999;91:1265-75. [DOI: 10.1016/s0306-4522(98)00715-5] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
368 D’souza D, Berman RM, Krystal JH, Charney DS. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biological Psychiatry 1999;46:1060-80. [DOI: 10.1016/s0006-3223(99)00209-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
369 Schwarz J, Scherer J, Trenkwalder C, Mozley P, Tatsch K. Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy? Psychiatry Research: Neuroimaging 1998;83:23-8. [DOI: 10.1016/s0925-4927(98)00026-2] [Cited by in Crossref: 12] [Article Influence: 0.5] [Reference Citation Analysis]
370 Riemer C. Antipsychotics. In: Peters J, editor. Polypharmacology in Drug Discovery. Hoboken: John Wiley & Sons, Inc.; 2012. pp. 343-62. [DOI: 10.1002/9781118098141.ch17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
371 Kaefer K, Malagon-Vina H, Dickerson DD, O'Neill J, Trossbach SV, Korth C, Csicsvari J. Disrupted-in-schizophrenia 1 overexpression disrupts hippocampal coding and oscillatory synchronization. Hippocampus 2019;29:802-16. [PMID: 30723982 DOI: 10.1002/hipo.23076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
372 Fallon JH, Opole IO, Potkin SG. The neuroanatomy of schizophrenia: circuitry and neurotransmitter systems. Clinical Neuroscience Research 2003;3:77-107. [DOI: 10.1016/s1566-2772(03)00022-7] [Cited by in Crossref: 31] [Article Influence: 1.7] [Reference Citation Analysis]
373 D'Ambrosio E, Jauhar S, Kim S, Veronese M, Rogdaki M, Pepper F, Bonoldi I, Kotoula V, Kempton MJ, Turkheimer F, Kwon JS, Kim E, Howes OD. The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study. Mol Psychiatry 2021;26:1332-45. [PMID: 31690805 DOI: 10.1038/s41380-019-0570-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
374 Segal M, Avital A, Derevenski A, Berstein S, Sandbank S, Weizman A. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone: . International Clinical Psychopharmacology 2007;22:192-6. [DOI: 10.1097/yic.0b013e3280803f3b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
375 Frankle WG. Neuroreceptor imaging studies in schizophrenia. Harv Rev Psychiatry 2007;15:212-32. [PMID: 17924257 DOI: 10.1080/10673220701679812] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
376 Aguilar-Valles A, Jung S, Poole S, Flores C, Luheshi GN. Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation. Psychoneuroendocrinology 2012;37:956-69. [PMID: 22133515 DOI: 10.1016/j.psyneuen.2011.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
377 Hagino Y, Moroji T. Effects of systematically administered ceruletide on the in vivo release and metabolism of dopamine in the medial prefrontal cortex of awake, freely moving rats: an in vivo microdialysis study. Brain Research 1994;644:40-6. [DOI: 10.1016/0006-8993(94)90344-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
378 Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Natesan S, Turkheimer F, Stone J, Egerton A, McGuire P, Kapur S, Howes OD. The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biol Psychiatry 2019;85:79-87. [PMID: 30122287 DOI: 10.1016/j.biopsych.2018.07.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
379 Thibaut F, Ribeyre J, Dourmap N, Meloni R, Laurent C, Campion D, Ménard J, Dollfus S, Mallet J, Petit M. Association of DNA polymorphism in the first intron of the tyrosine hydroxylase gene with disturbances of the catecholaminergic system in schizophrenia. Schizophrenia Research 1997;23:259-64. [DOI: 10.1016/s0920-9964(96)00118-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
380 Mohr C, Landis T, Sandor PS, Fathi M, Brugger P. Nonstereotyped responding in positive schizotypy after a single dose of levodopa. Neuropsychopharmacology 2004;29:1741-51. [PMID: 15173845 DOI: 10.1038/sj.npp.1300500] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
381 Prus AJ, Huang M, Li Z, Dai J, Meltzer HY. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: Potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Brain Research 2007;1184:354-64. [DOI: 10.1016/j.brainres.2007.09.092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
382 Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, Nagatsu T. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm Gen Sect 1994;8:149-58. [DOI: 10.1007/bf02250926] [Cited by in Crossref: 66] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
383 Donegan JJ, Tyson JA, Branch SY, Beckstead MJ, Anderson SA, Lodge DJ. Stem cell-derived interneuron transplants as a treatment for schizophrenia: preclinical validation in a rodent model. Mol Psychiatry 2017;22:1492-501. [PMID: 27480492 DOI: 10.1038/mp.2016.121] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
384 Tateno A, Sakayori T, Kim WC, Honjo K, Nakayama H, Arakawa R, Okubo Y. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO. Int J Neuropsychopharmacol 2018;21:522-7. [PMID: 29346639 DOI: 10.1093/ijnp/pyy004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
385 Chen CY, Liu CY, Yang YY. Correlation of panic attacks and hostility in chronic schizophrenia. Psychiatry Clin Neurosci 2001;55:383-7. [PMID: 11442890 DOI: 10.1046/j.1440-1819.2001.00879.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
386 Laplante F, Zhang ZW, Huppé-Gourgues F, Dufresne MM, Vaucher E, Sullivan RM. Cholinergic depletion in nucleus accumbens impairs mesocortical dopamine activation and cognitive function in rats. Neuropharmacology 2012;63:1075-84. [PMID: 22842071 DOI: 10.1016/j.neuropharm.2012.07.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
387 Yan Z, Hsieh–wilson L, Feng J, Tomizawa K, Allen PB, Fienberg AA, Nairn AC, Greengard P. Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP–32 and spinophilin. Nat Neurosci 1999;2:13-7. [DOI: 10.1038/4516] [Cited by in Crossref: 195] [Cited by in F6Publishing: 199] [Article Influence: 8.9] [Reference Citation Analysis]
388 Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clinical Therapeutics 2005;27:S25-37. [DOI: 10.1016/j.clinthera.2005.07.015] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
389 Conio B, Martino M, Magioncalda P, Escelsior A, Inglese M, Amore M, Northoff G. Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry 2020;25:82-93. [PMID: 30953003 DOI: 10.1038/s41380-019-0406-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 24.5] [Reference Citation Analysis]
390 Jönsson E, Brené S, Geijer T, Terenius L, Tylec A, Persson M-, Sedvall G. A search for association between schizophrenia and dopamine-related alleles. Eur Arch Psychiatry Clin Nuerosci 1996;246:297-304. [DOI: 10.1007/bf02189022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
391 Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008;258:16-27. [PMID: 17901997 DOI: 10.1007/s00406-007-0757-8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
392 Pillai A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals. 2008;16:183-193. [PMID: 18253057 DOI: 10.1159/000111562] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 6.2] [Reference Citation Analysis]
393 Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012;17:1206-27. [PMID: 22584864 DOI: 10.1038/mp.2012.47] [Cited by in Crossref: 342] [Cited by in F6Publishing: 243] [Article Influence: 38.0] [Reference Citation Analysis]
394 Ford JM, Roth WT. Deficient response modulation of event-related brain potentials in schizophrenia: . Current Opinion in Psychiatry 2004;17:91-6. [DOI: 10.1097/00001504-200403000-00005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
395 Artiges E, Leroy C, Dubol M, Prat M, Pepin A, Mabondo A, de Beaurepaire R, Beaufils B, Korwin JP, Galinowski A, D'Albis MA, Santiago-Ribeiro MJ, Granger B, Tzavara ET, Martinot JL, Trichard C. Striatal and Extrastriatal Dopamine Transporter Availability in Schizophrenia and Its Clinical Correlates: A Voxel-Based and High-Resolution PET Study. Schizophr Bull 2017;43:1134-42. [PMID: 28177089 DOI: 10.1093/schbul/sbw192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
396 Morris SE, Holroyd CB, Mann-Wrobel MC, Gold JM. Dissociation of response and feedback negativity in schizophrenia: electrophysiological and computational evidence for a deficit in the representation of value. Front Hum Neurosci 2011;5:123. [PMID: 22065618 DOI: 10.3389/fnhum.2011.00123] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
397 Abi-dargham A, Krystal J. Serotonin Receptors as Targets of Antipsychotic Medications. In: Lidow M, editor. Neurotransmitter Receptors in Actions of Antipsychotic Medications. CRC Press; 2000. pp. 79-107. [DOI: 10.1201/9781420041774.ch6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
398 Sweet RA, Pollock BG, Mulsant BH, Rosen J, Lo KH, Yao JK, Henteleff RA, Mazumdar S. Association of Plasma Homovanillic Acid with Behavioral Symptoms in Patients Diagnosed with Dementia: A Preliminary Report. Biological Psychiatry 1997;42:1016-23. [DOI: 10.1016/s0006-3223(97)00146-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
399 Goff D. Glutamate Receptors in Schizophrenia and Antipsychotic Drugs. In: Lidow M, editor. Neurotransmitter Receptors in Actions of Antipsychotic Medications. CRC Press; 2000. pp. 121-36. [DOI: 10.1201/9781420041774.ch8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
400 Lataster J, Collip D, Ceccarini J, Haas D, Booij L, van Os J, Pruessner J, Van Laere K, Myin-Germeys I. Psychosocial stress is associated with in vivo dopamine release in human ventromedial prefrontal cortex: a positron emission tomography study using [¹⁸F]fallypride. Neuroimage 2011;58:1081-9. [PMID: 21801840 DOI: 10.1016/j.neuroimage.2011.07.030] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 6.8] [Reference Citation Analysis]
401 Holloway ZR, Freels TG, Comstock JF, Nolen HG, Sable HJ, Lester DB. Comparing phasic dopamine dynamics in the striatum, nucleus accumbens, amygdala, and medial prefrontal cortex. Synapse 2018;:e22074. [PMID: 30317673 DOI: 10.1002/syn.22074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
402 Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol. 2007;78:1-39. [PMID: 17349856 DOI: 10.1016/s0074-7742(06)78001-1] [Cited by in Crossref: 202] [Cited by in F6Publishing: 74] [Article Influence: 16.8] [Reference Citation Analysis]
403 Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 2004;29:300-7. [PMID: 14560321 DOI: 10.1038/sj.npp.1300313] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
404 Kao Y, Liu Y, Cheng T, Chou M. Cigarette smoking in outpatients with chronic schizophrenia in Taiwan: Relationships to socio-demographic and clinical characteristics. Psychiatry Research 2011;190:193-9. [DOI: 10.1016/j.psychres.2011.05.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
405 Angelucci F, Ricci V, Spalletta G, Caltagirone C, Mathé AA, Bria P. Effects of psychostimulants on neurotrophins implications for psychostimulant-induced neurotoxicity. Int Rev Neurobiol 2009;88:1-24. [PMID: 19897072 DOI: 10.1016/S0074-7742(09)88001-X] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
406 Acharya S, Kim KM. Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease. Int J Mol Sci 2021;22:4299. [PMID: 33919025 DOI: 10.3390/ijms22094299] [Reference Citation Analysis]
407 Lewis DA, Akil M. Cortical dopamine in schizophrenia: Strategies for postmortem studies. Journal of Psychiatric Research 1997;31:175-95. [DOI: 10.1016/s0022-3956(96)00057-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
408 Surguladze SA, Chu EM, Marshall N, Evans A, Anilkumar AP, Timehin C, McDonald C, Ecker C, Phillips ML, David AS. Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. J Psychopharmacol 2011;25:722-33. [PMID: 20360158 DOI: 10.1177/0269881110363316] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
409 Pallone KA, Goldman MP, Fuller MA. Isoniazid-associated psychosis: case report and review of the literature. Ann Pharmacother 1993;27:167-70. [PMID: 8439690 DOI: 10.1177/106002809302700205] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
410 Harrison PJ. Dopamine and schizophrenia—proof at last? The Lancet 2000;356:958-9. [DOI: 10.1016/s0140-6736(00)02710-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
411 Chen DC, Du XD, Yin GZ, Yang KB, Nie Y, Wang N, Li YL, Xiu MH, He SC, Yang FD, Cho RY, Kosten TR, Soares JC, Zhao JP, Zhang XY. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits. Psychol Med 2016;46:3219-30. [DOI: 10.1017/s0033291716001902] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 5.6] [Reference Citation Analysis]
412 Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002;26:553-60. [DOI: 10.1016/s0278-5846(01)00307-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
413 Aman MG, Madrid A. Atypical antipsychotics in persons with developmental disabilities. Ment Retard Dev Disabil Res Rev 1999;5:253-63. [DOI: 10.1002/(sici)1098-2779(1999)5:4<253::aid-mrdd2>3.0.co;2-r] [Cited by in Crossref: 32] [Article Influence: 1.5] [Reference Citation Analysis]
414 Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA. Decreased density of tyrosine hydroxylase–immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biological Psychiatry 2000;47:361-70. [DOI: 10.1016/s0006-3223(99)00282-6] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
415 Chakravarty MM, Rapoport JL, Giedd JN, Raznahan A, Shaw P, Collins DL, Lerch JP, Gogtay N. Striatal shape abnormalities as novel neurodevelopmental endophenotypes in schizophrenia: a longitudinal study. Hum Brain Mapp 2015;36:1458-69. [PMID: 25504933 DOI: 10.1002/hbm.22715] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
416 Edwards AC, Bacanu SA, Bigdeli TB, Moscati A, Kendler KS. Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study. Schizophr Res 2016;176:136-40. [PMID: 27338758 DOI: 10.1016/j.schres.2016.06.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 5.4] [Reference Citation Analysis]
417 Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol 2010;92:370-85. [PMID: 20624444 DOI: 10.1016/j.pneurobio.2010.06.010] [Cited by in Crossref: 192] [Cited by in F6Publishing: 140] [Article Influence: 17.5] [Reference Citation Analysis]
418 Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol 2016;30:428-35. [PMID: 26966119 DOI: 10.1177/0269881116636120] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
419 Borroto-Escuela DO, Pintsuk J, Schäfer T, Friedland K, Ferraro L, Tanganelli S, Liu F, Fuxe K. Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia. Ther Adv Psychopharmacol 2016;6:77-94. [PMID: 27141290 DOI: 10.1177/2045125316637570] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
420 Dai D, Wang Y, Yuan J, Zhou X, Jiang D, Li J, Zhang Y, Yin H, Duan S. Meta-analyses of 10 polymorphisms associated with the risk of schizophrenia. Biomed Rep 2014;2:729-36. [PMID: 25054019 DOI: 10.3892/br.2014.308] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
421 Myin-Germeys I, Marcelis M, Krabbendam L, Delespaul P, van Os J. Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry 2005;58:105-10. [PMID: 16038680 DOI: 10.1016/j.biopsych.2005.02.012] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 4.3] [Reference Citation Analysis]
422 Silvestrini B, Palmery M, Tolu L, Basta F, Leone MG, Yan Cheng C. Facilins, a novel class of biological factors that facilitate the aortic response to dopamine and other biogenic amines. J Neural Transmission 1994;95:77-93. [DOI: 10.1007/bf01276427] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
423 Wong AH, Van Tol HH. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev. 2003;27:269-306. [PMID: 12788337 DOI: 10.1016/s0149-7634(03)00035-6] [Cited by in Crossref: 172] [Cited by in F6Publishing: 39] [Article Influence: 9.6] [Reference Citation Analysis]
424 Chung Y, Li Z, Dai J, Meltzer HY, Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Research 2004;1023:54-63. [DOI: 10.1016/j.brainres.2004.07.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 4.2] [Reference Citation Analysis]
425 Yoon JH, Minzenberg MJ, Raouf S, D'Esposito M, Carter CS. Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol Psychiatry 2013;74:122-9. [PMID: 23290498 DOI: 10.1016/j.biopsych.2012.11.018] [Cited by in Crossref: 92] [Cited by in F6Publishing: 69] [Article Influence: 11.5] [Reference Citation Analysis]
426 Willner P. Dopamine and Depression. In: Di Chiara G, editor. Dopamine in the CNS II. Berlin: Springer Berlin Heidelberg; 2002. pp. 387-416. [DOI: 10.1007/978-3-662-06765-9_12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
427 Shukla DK, Chiappelli JJ, Sampath H, Kochunov P, Hare SM, Wisner K, Rowland LM, Hong LE. Aberrant Frontostriatal Connectivity in Negative Symptoms of Schizophrenia. Schizophr Bull 2019;45:1051-9. [PMID: 30576563 DOI: 10.1093/schbul/sby165] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
428 Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep. 2007;9:329-336. [PMID: 17880866 DOI: 10.1007/s11920-007-0041-7] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 9.4] [Reference Citation Analysis]
429 Harrison PJ. The neuropathology of schizophrenia. Brain 1999;122:593-624. [DOI: 10.1093/brain/122.4.593] [Cited by in Crossref: 1097] [Cited by in F6Publishing: 958] [Article Influence: 49.9] [Reference Citation Analysis]
430 Lacroix L, Spinelli S, White W, Feldon J. The effects of ibotenic acid lesions of the medial and lateral prefrontal cortex on latent inhibition, prepulse inhibition and amphetamine-induced hyperlocomotion. Neuroscience 2000;97:459-68. [DOI: 10.1016/s0306-4522(00)00013-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
431 Kellendonk C. Modeling excess striatal D2 receptors in mice. Genetic Models of Schizophrenia. Elsevier; 2009. pp. 59-65. [DOI: 10.1016/s0079-6123(09)17907-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
432 Fournier M, Ferrari C, Baumann PS, Polari A, Monin A, Bellier-Teichmann T, Wulff J, Pappan KL, Cuenod M, Conus P, Do KQ. Impaired metabolic reactivity to oxidative stress in early psychosis patients. Schizophr Bull 2014;40:973-83. [PMID: 24687046 DOI: 10.1093/schbul/sbu053] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
433 Meyer-Lindenberg A. From maps to mechanisms through neuroimaging of schizophrenia. Nature. 2010;468:194-202. [PMID: 21068827 DOI: 10.1038/nature09569] [Cited by in Crossref: 200] [Cited by in F6Publishing: 156] [Article Influence: 18.2] [Reference Citation Analysis]
434 Kellendonk C, Simpson EH, Kandel ER. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci 2009;32:347-58. [PMID: 19409625 DOI: 10.1016/j.tins.2009.02.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 8.8] [Reference Citation Analysis]
435 Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35. [PMID: 8097114 DOI: 10.1016/0006-3223(93)90288-o] [Cited by in Crossref: 340] [Cited by in F6Publishing: 70] [Article Influence: 12.1] [Reference Citation Analysis]
436 Wang Y, Fang Y, Shen Y, Xu Q. Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Research 2010;179:147-50. [DOI: 10.1016/j.psychres.2009.03.029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
437 Llewellyn S. In two minds? Is schizophrenia a state ‘trapped’ between waking and dreaming? Medical Hypotheses 2009;73:572-9. [DOI: 10.1016/j.mehy.2009.05.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
438 Arroll MA, Wilder L, Neil J. Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J 2014;13:91. [PMID: 25228271 DOI: 10.1186/1475-2891-13-91] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.9] [Reference Citation Analysis]
439 Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull 2013;39:22-32. [PMID: 22282456 DOI: 10.1093/schbul/sbr111] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 7.3] [Reference Citation Analysis]
440 Hou Y, Yang JY, Wu CF, Huang M. Effects of clozapine, olanzapine and haloperidol on ethanol-induced ascorbic acid release in mouse striatum. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005;29:83-9. [DOI: 10.1016/j.pnpbp.2004.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
441 Henderson DC, Ettinger ER. Schizophrenia and diabetes. Glucose Metabolism in the Brain. Elsevier; 2002. pp. 481-501. [DOI: 10.1016/s0074-7742(02)51014-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
442 de Leeuw M, Kahn RS, Vink M. Fronto-striatal dysfunction during reward processing in unaffected siblings of schizophrenia patients. Schizophr Bull 2015;41:94-103. [PMID: 25368371 DOI: 10.1093/schbul/sbu153] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
443 Friedman JI, Davis KL. Special issue: Molecular mechanisms of schizophrenia. Biol Psychiatry 2006;60:527-9. [PMID: 16996999 DOI: 10.1016/j.biopsych.2006.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
444 Nazimek JM, Hunter MD, Woodruff PW. Auditory hallucinations: expectation-perception model. Med Hypotheses 2012;78:802-10. [PMID: 22520337 DOI: 10.1016/j.mehy.2012.03.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
445 Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biological Psychiatry 1998;44:1099-117. [DOI: 10.1016/s0006-3223(98)00187-5] [Cited by in Crossref: 147] [Cited by in F6Publishing: 17] [Article Influence: 6.4] [Reference Citation Analysis]
446 Chalkiadaki K, Velli A, Kyriazidis E, Stavroulaki V, Vouvoutsis V, Chatzaki E, Aivaliotis M, Sidiropoulou K. Development of the MAM model of schizophrenia in mice: Sex similarities and differences of hippocampal and prefrontal cortical function. Neuropharmacology 2019;144:193-207. [DOI: 10.1016/j.neuropharm.2018.10.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
447 Lidow MS. D1- and D2 dopaminergic receptors in the developing cerebral cortex of macaque monkey: a film autoradiographic study. Neuroscience 1995;65:439-52. [PMID: 7777159 DOI: 10.1016/0306-4522(94)00475-k] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
448 Wang X, Zhong P, Gu Z, Yan Z. Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex. J Neurosci 2003;23:9852-61. [PMID: 14586014 [PMID: 14586014 DOI: 10.1523/jneurosci.23-30-09852.2003] [Cited by in Crossref: 115] [Article Influence: 6.4] [Reference Citation Analysis]
449 Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl) 2004;175:473-80. [PMID: 15083259 DOI: 10.1007/s00213-004-1852-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 0.1] [Reference Citation Analysis]
450 Tozzi A, Guatteo E, Caputi L, Bernardi G, Mercuri NB. Group I mGluRs coupled to G proteins are regulated by tyrosine kinase in dopamine neurons of the rat midbrain. J Neurophysiol 2001;85:2490-7. [PMID: 11387395 DOI: 10.1152/jn.2001.85.6.2490] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
451 Amitai N, Powell S, Weber M, Swerdlow NR, Young JW. Negative visuospatial priming in isolation-reared rats: Evidence of resistance to the disruptive effects of amphetamine. Cogn Affect Behav Neurosci 2015;15:901-14. [PMID: 26220402 DOI: 10.3758/s13415-015-0369-0] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
452 Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biological Psychiatry 1999;45:680-6. [DOI: 10.1016/s0006-3223(98)00258-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
453 Scornaiencki R, Cantrup R, Rushlow WJ, Rajakumar N. Prefrontal cortical D1 dopamine receptors modulate subcortical D2 dopamine receptor-mediated stress responsiveness. Int J Neuropsychopharm 2009;12:1195. [DOI: 10.1017/s1461145709000121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
454 Wahl L, Nahmias C. Quantification of dopamine metabolism in man: a mathematically justifiable approach. Phys Med Biol 1996;41:963-78. [DOI: 10.1088/0031-9155/41/6/002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
455 Lung F, Chen N, Shu B. Dopamine D4 receptor gene and the −521C>T polymorphism of the upstream region of the dopamine D4 receptor gene in schizophrenia. Psychiatric Genetics 2006;16:139-43. [DOI: 10.1097/01.ypg.0000199446.54420.ff] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
456 Mackintosh AJ, de Bock R, Lim Z, Trulley VN, Schmidt A, Borgwardt S, Andreou C. Psychotic disorders, dopaminergic agents and EEG/MEG resting-state functional connectivity: A systematic review. Neurosci Biobehav Rev 2021;120:354-71. [PMID: 33171145 DOI: 10.1016/j.neubiorev.2020.10.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
457 van Berckel BNM, Kegeles LS, Waterhouse R, Guo N, Hwang D, Huang Y, Narendran R, Van Heertum R, Laruelle M. Modulation of Amphetamine-Induced Dopamine Release by Group II Metabotropic Glutamate Receptor Agonist LY354740 in Non-Human Primates Studied with Positron Emission Tomography. Neuropsychopharmacol 2006;31:967-77. [DOI: 10.1038/sj.npp.1300902] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
458 Gong R, Ding C, Hu J, Lu Y, Liu F, Mann E, Xu F, Cohen MB, Luo M. Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior. Science 2011;333:1642-6. [PMID: 21835979 DOI: 10.1126/science.1207675] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
459 McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids 2006;75:329-49. [PMID: 16949263 DOI: 10.1016/j.plefa.2006.07.010] [Cited by in Crossref: 348] [Cited by in F6Publishing: 265] [Article Influence: 23.2] [Reference Citation Analysis]
460 Maksymetz J, Moran SP, Conn PJ. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. Mol Brain. 2017;10:15. [PMID: 28446243 DOI: 10.1186/s13041-017-0293-z] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 15.5] [Reference Citation Analysis]
461 Ozyurt B, Sarsilmaz M, Akpolat N, Ozyurt H, Akyol O, Herken H, Kus I. The protective effects of omega-3 fatty acids against MK-801-induced neurotoxicity in prefrontal cortex of rat. Neurochem Int 2007;50:196-202. [PMID: 16971021 DOI: 10.1016/j.neuint.2006.08.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
462 Kodesh A, Weizman A, Aizenberg D, Hermesh H, Gelkopf M, Zemishlany Z. Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study. Clin Neuropharmacol 2003;26:193-5. [PMID: 12897639 DOI: 10.1097/00002826-200307000-00008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
463 Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 1997;11:151-62. [PMID: 9208378 DOI: 10.1177/026988119701100208] [Cited by in Crossref: 304] [Cited by in F6Publishing: 273] [Article Influence: 12.7] [Reference Citation Analysis]
464 Sakayori T, Tateno A, Arakawa R, Kim WC, Okubo Y. Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients. Psychopharmacology (Berl) 2021;238:1343-50. [PMID: 33180175 DOI: 10.1007/s00213-020-05698-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
465 Llewellyn S. Is 'bipolar disorder' the brain's autopoietic response to schizophrenia? Med Hypotheses 2009;73:580-4. [PMID: 19589644 DOI: 10.1016/j.mehy.2009.05.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
466 Scharfetter J. Dopamine receptor polymorphisms and drug response in schizophrenia. Pharmacogenomics 2001;2:251-61. [DOI: 10.1517/14622416.2.3.251] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
467 Konings M, Stefanis N, Kuepper R, de Graaf R, ten Have M, van Os J, Bakoula C, Henquet C. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol Med 2012;42:149-59. [PMID: 21676285 DOI: 10.1017/S0033291711000973] [Cited by in Crossref: 68] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
468 Kritzer MF. Perinatal gonadectomy exerts regionally selective, lateralized effects on the density of axons immunoreactive for tyrosine hydroxylase in the cerebral cortex of adult male rats. J Neurosci 1998;18:10735-48. [PMID: 9852608 [PMID: 9852608 DOI: 10.1523/jneurosci.18-24-10735.1998] [Cited by in Crossref: 13] [Article Influence: 0.6] [Reference Citation Analysis]
469 Chen Y, McBain R, Norton D, Ongur D. Schizophrenia patients show augmented spatial frame illusion for visual and visuomotor tasks. Neuroscience 2011;172:419-26. [PMID: 20971162 DOI: 10.1016/j.neuroscience.2010.10.039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
470 Gómez J, Jesús Marín-méndez J, Molero P, Atakan Z, Ortuño F. Time perception networks and cognition in schizophrenia: A review and a proposal. Psychiatry Research 2014;220:737-44. [DOI: 10.1016/j.psychres.2014.07.048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
471 Radhakrishnan R, Wilkinson ST, D'Souza DC. Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry 2014;5:54. [PMID: 24904437 DOI: 10.3389/fpsyt.2014.00054] [Cited by in Crossref: 139] [Cited by in F6Publishing: 91] [Article Influence: 19.9] [Reference Citation Analysis]
472 Perreault ML, O'Dowd BF, George SR. Dopamine receptor homooligomers and heterooligomers in schizophrenia. CNS Neurosci Ther 2011;17:52-7. [PMID: 21199449 DOI: 10.1111/j.1755-5949.2010.00228.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
473 Lynch MR. Selective effects on prefrontal cortex serotonin by dopamine D3 receptor agonism: Interaction with low-dose haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1997;21:1141-53. [DOI: 10.1016/s0278-5846(97)00106-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
474 Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res. 2014;152:325-332. [PMID: 24418122 DOI: 10.1016/j.schres.2013.12.013] [Cited by in Crossref: 112] [Cited by in F6Publishing: 86] [Article Influence: 16.0] [Reference Citation Analysis]
475 Zhang B, Guo F, Ma Y, Song Y, Lin R, Shen FY, Jin GZ, Li Y, Liu ZQ. Activation of D1R/PKA/mTOR signaling cascade in medial prefrontal cortex underlying the antidepressant effects of l-SPD. Sci Rep 2017;7:3809. [PMID: 28630404 DOI: 10.1038/s41598-017-03680-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
476 Xing G, Zhang L, Russell S, Post R. Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders. Schizophr Res 2006;84:36-56. [PMID: 16631355 DOI: 10.1016/j.schres.2005.11.006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
477 MacQueen DA, Young JW. The D2-family receptor agonist bromocriptine but, not nicotine, reverses NMDA receptor antagonist-induced working memory deficits in the radial arm maze in mice. Neurobiol Learn Mem 2020;168:107159. [PMID: 31911198 DOI: 10.1016/j.nlm.2020.107159] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
478 Schweimer JV, Coullon GS, Betts JF, Burnet PW, Engle SJ, Brandon NJ, Harrison PJ, Sharp T. Increased burst-firing of ventral tegmental area dopaminergic neurons in D-amino acid oxidase knockout mice in vivo. Eur J Neurosci 2014;40:2999-3009. [PMID: 25040393 DOI: 10.1111/ejn.12667] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
479 Mathalon DH, Jorgensen KW, Roach BJ, Ford JM. Error detection failures in schizophrenia: ERPs and FMRI. Int J Psychophysiol 2009;73:109-17. [PMID: 19414043 DOI: 10.1016/j.ijpsycho.2009.02.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
480 Shonberg J, Herenbrink CK, López L, Christopoulos A, Scammells PJ, Capuano B, Lane JR. A structure-activity analysis of biased agonism at the dopamine D2 receptor. J Med Chem 2013;56:9199-221. [PMID: 24138311 DOI: 10.1021/jm401318w] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
481 Cropley VL, Fujita M, Innis RB, Nathan PJ. Molecular Imaging of the Dopaminergic System and its Association with Human Cognitive Function. Biological Psychiatry 2006;59:898-907. [DOI: 10.1016/j.biopsych.2006.03.004] [Cited by in Crossref: 179] [Cited by in F6Publishing: 142] [Article Influence: 11.9] [Reference Citation Analysis]
482 Lewis DA, González-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2008;33:141-65. [PMID: 17805309 DOI: 10.1038/sj.npp.1301563] [Cited by in Crossref: 247] [Cited by in F6Publishing: 227] [Article Influence: 17.6] [Reference Citation Analysis]
483 Ohmori T, Koyama T, Inoue T, Matsubara S, Yamashita I. B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia. Biol Psychiatry 1993;33:687-93. [PMID: 8102551 DOI: 10.1016/0006-3223(93)90117-v] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
484 Smith RS. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 1992;39:248-57. [PMID: 1361959 DOI: 10.1016/0306-9877(92)90117-u] [Cited by in Crossref: 93] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
485 Spitzer M. The psychopathology, neuropsychology, and neurobiology of associative and working memory in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1993;243:57-70. [PMID: 8218428 DOI: 10.1007/BF02191566] [Cited by in Crossref: 82] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
486 Inserra A, De Gregorio D, Gobbi G. Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacol Rev 2021;73:202-77. [PMID: 33328244 DOI: 10.1124/pharmrev.120.000056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
487 Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996;317:417-23. [PMID: 8997630 DOI: 10.1016/s0014-2999(96)00840-0] [Cited by in Crossref: 65] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
488 Amato D, Vernon AC, Papaleo F. Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability. Neuroscience & Biobehavioral Reviews 2018;85:146-59. [DOI: 10.1016/j.neubiorev.2017.09.027] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
489 Alimohamad H, Sutton L, Mouyal J, Rajakumar N, Rushlow WJ. The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J Neurochem 2005;95:513-25. [PMID: 16144542 DOI: 10.1111/j.1471-4159.2005.03388.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]
490 Brady LJ, Bartley AF, Li Q, McMeekin LJ, Hablitz JJ, Cowell RM, Dobrunz LE. Transcriptional dysregulation causes altered modulation of inhibition by haloperidol. Neuropharmacology 2016;111:304-13. [PMID: 27480797 DOI: 10.1016/j.neuropharm.2016.07.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
491 Bardgett ME, Jacobs PS, Jackson JL, Csernansky JG. Kainic acid lesions enhance locomotor responses to novelty, saline, amphetamine, and MK-801. Behavioural Brain Research 1997;84:47-55. [DOI: 10.1016/s0166-4328(96)00132-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
492 Erritzoe D, Talbot P, Frankle W, Abi-dargham A. Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. Neuroimaging Clinics of North America 2003;13:817-32. [DOI: 10.1016/s1052-5149(03)00089-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
493 Sami MB, Rabiner EA, Bhattacharyya S. Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. European Neuropsychopharmacology 2015;25:1201-24. [DOI: 10.1016/j.euroneuro.2015.03.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
494 Chen Y, Bidwell LC, Norton D. Trait vs. State Markers for Schizophrenia: Identification and Characterization through Visual Processes. Curr Psychiatry Rev 2006;2:431-8. [PMID: 17487285 DOI: 10.2174/157340006778699729] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
495 Healy-Stoffel M, Levant B. N-3 (Omega-3) Fatty Acids: Effects on Brain Dopamine Systems and Potential Role in the Etiology and Treatment of Neuropsychiatric Disorders. CNS Neurol Disord Drug Targets 2018;17:216-32. [PMID: 29651972 DOI: 10.2174/1871527317666180412153612] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 20.5] [Reference Citation Analysis]
496 Malm J, Kristensen B, Ekstedt J, Wester P. CSF concentration gradients of monoamine metabolites in patients with hydrocephalus. J Neurol Neurosurg Psychiatry 1994;57:1026-33. [PMID: 7522267 DOI: 10.1136/jnnp.57.9.1026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
497 Sotty F, Brun P, Leonetti M, Steinberg R, Soubrié P, Renaud B, Suaud-chagny M. Comparative effects of neurotensin, neurotensin(8-13) and [D-Tyr11]neurotensin applied into the ventral tegmental area on extracellular dopamine in the rat prefrontal cortex and nucleus accumbens. Neuroscience 2000;98:485-92. [DOI: 10.1016/s0306-4522(00)90023-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
498 Rosen C, Jones N, Chase KA, Melbourne JK, Grossman LS, Sharma RP. Immersion in altered experience: An investigation of the relationship between absorption and psychopathology. Conscious Cogn 2017;49:215-26. [PMID: 28219788 DOI: 10.1016/j.concog.2017.01.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
499 Rampino A, Torretta S, Gelao B, Veneziani F, Iacoviello M, Marakhovskaya A, Masellis R, Andriola I, Sportelli L, Pergola G, Minelli A, Magri C, Gennarelli M, Vita A, Beaulieu JM, Bertolino A, Blasi G. Evidence of an interaction between FXR1 and GSK3β polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics. Eur Psychiatry 2021;64:e39. [PMID: 33866994 DOI: 10.1192/j.eurpsy.2021.26] [Reference Citation Analysis]
500 [DOI: 10.1101/369314] [Cited by in Crossref: 4] [Reference Citation Analysis]
501 Hsu M, Chen Y, Lee C, Chiu H. Gold Nanostructures on Flexible Substrates as Electrochemical Dopamine Sensors. ACS Appl Mater Interfaces 2012;4:5570-5. [DOI: 10.1021/am301452b] [Cited by in Crossref: 101] [Cited by in F6Publishing: 51] [Article Influence: 11.2] [Reference Citation Analysis]
502 Peleg-raibstein D, Feldon J. Effects of withdrawal from an escalating dose of amphetamine on conditioned fear and dopamine response in the medial prefrontal cortex. Behavioural Brain Research 2008;186:12-22. [DOI: 10.1016/j.bbr.2007.07.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
503 Ichikawa J, Chung Y, Dai J, Meltzer HY. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain Research 2005;1052:56-62. [DOI: 10.1016/j.brainres.2005.06.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
504 Miotto P, Pollini B, Restaneo A, Favaretto G, Sisti D, Rocchi MB, Preti A. Symptoms of psychosis in anorexia and bulimia nervosa. Psychiatry Res. 2010;175:237-243. [PMID: 20022383 DOI: 10.1016/j.psychres.2009.03.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
505 Wilson JM, Sanyal S, Van Tol HH. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. Eur J Pharmacol 1998;351:273-86. [PMID: 9721018 DOI: 10.1016/s0014-2999(98)00312-4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
506 Miotto P, Preti A, Frezza M. Heroin and schizophrenia: subjective responses to abused drugs in dually diagnosed patients. J Clin Psychopharmacol 2001;21:111-3. [PMID: 11199935 DOI: 10.1097/00004714-200102000-00022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
507 Sui ZY, Li C, Huang G, Kwon Y, Kim K, Lee K, Chung Y. Age-specific effects of 6-hydroxydopamine lesions of the rat medial prefrontal cortex on stress-induced c-fos expression in subcortical areas. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010;34:1054-9. [DOI: 10.1016/j.pnpbp.2010.05.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
508 Liégeois J, Ichikawa J, Meltzer HY. 5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Research 2002;947:157-65. [DOI: 10.1016/s0006-8993(02)02620-3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
509 Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 2007;62:739-46. [PMID: 17511968 DOI: 10.1016/j.biopsych.2006.12.003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 5.7] [Reference Citation Analysis]
510 Jiang W, Shang S, Su Y. Genetic influences on insight problem solving: the role of catechol-O-methyltransferase (COMT) gene polymorphisms. Front Psychol 2015;6:1569. [PMID: 26528222 DOI: 10.3389/fpsyg.2015.01569] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
511 Zigelboim I, Weissberg A, Cohen Y. Target-Specific Ligands and Gadolinium-Based Complexes for Imaging of Dopamine Receptors: Synthesis, Binding Affinity, and Relaxivity. J Org Chem 2013;78:7001-12. [DOI: 10.1021/jo400646k] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
512 Colombo ML, McNeil S, Iwai N, Chang A, Shen M. Electrochemical Detection of Dopamine via Assisted Ion Transfer at Nanopipet Electrode Using Cyclic Voltammetry. J Electrochem Soc 2016;163:H3072-6. [PMID: 29606735 DOI: 10.1149/2.0091604jes] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
513 Spitzer M. Conceptual developments in the neurosciences relevant to psychiatry: . Current Opinion in Psychiatry 1995;8:317-29. [DOI: 10.1097/00001504-199509000-00011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
514 Goto Y, Grace AA. The Dopamine System and the Pathophysiology of Schizophrenia: A Basic Science Perspective. Integrating the Neurobiology of Schizophrenia. Elsevier; 2007. pp. 41-68. [DOI: 10.1016/s0074-7742(06)78002-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
515 Sullivan R, Szechtman H. Asymmetrical influence of mesocortical dopamine depletion on stress ulcer development and subcortical dopamine systems in rats: Implications for psychopathology. Neuroscience 1995;65:757-66. [DOI: 10.1016/0306-4522(94)00531-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 2.2] [Reference Citation Analysis]
516 Ben-Azu B, Aderibigbe AO, Omogbiya IA, Ajayi AM, Owoeye O, Olonode ET, Iwalewa EO. Probable mechanisms involved in the antipsychotic-like activity of morin in mice. Biomed Pharmacother 2018;105:1079-90. [PMID: 30021344 DOI: 10.1016/j.biopha.2018.06.057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 6.3] [Reference Citation Analysis]
517 da Silva Alves F, Bakker G, Schmitz N, Abeling N, Hasler G, van der Meer J, Nederveen A, de Haan L, Linszen D, van Amelsvoort T. Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study. Eur Neuropsychopharmacol 2013;23:1577-86. [PMID: 23978392 DOI: 10.1016/j.euroneuro.2013.06.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
518 Ward RD, Kellendonk C, Kandel ER, Balsam PD. Timing as a window on cognition in schizophrenia. Neuropharmacology 2012;62:1175-81. [PMID: 21530549 DOI: 10.1016/j.neuropharm.2011.04.014] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
519 Laplante F, Brake WG, Chehab SL, Sullivan RM. Sex differences in the effects of perinatal anoxia on dopamine function in rats. Neuroscience Letters 2012;506:89-93. [DOI: 10.1016/j.neulet.2011.10.055] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
520 Bertolino A. Dysregulation of dopamine and pathology of prefrontal neurons: neuroimaging studies in schizophrenia and related animal models. Epidemiol Psychiatr Sci 1999;8:248-54. [DOI: 10.1017/s1121189x00008150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
521 Soares JC, Innis RB. Neurochemical brain imaging investigations of schizophrenia. Biological Psychiatry 1999;46:600-15. [DOI: 10.1016/s0006-3223(99)00015-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
522 Javitt DC, Hashim A, Sershen H. Modulation of striatal dopamine release by glycine transport inhibitors. Neuropsychopharmacology 2005;30:649-56. [PMID: 15688094 DOI: 10.1038/sj.npp.1300589] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
523 Jönsson EG, Nöthen MM, Neidt H, Forslund K, Rylander G, Mattila-Evenden M, Asberg M, Propping P, Sedvall GC. Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr Res 1999;40:31-6. [PMID: 10541004 DOI: 10.1016/s0920-9964(99)00033-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
524 Zhang XY, Chen DC, Xiu MH, Haile CN, Sun H, Lu L, Kosten TA, Kosten TR. Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study. PLoS One 2012;7:e36563. [PMID: 22570726 DOI: 10.1371/journal.pone.0036563] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
525 Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function: Focus on monoaminergic neurotransmission. Lipids 2001;36:937-44. [DOI: 10.1007/s11745-001-0804-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 91] [Article Influence: 6.1] [Reference Citation Analysis]
526 Leyton M, Corin E, Martial J, Meaney M. Psychotic symptoms and vulnerability to recurrent major depression. Journal of Affective Disorders 1995;33:107-15. [DOI: 10.1016/0165-0327(94)00080-s] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
527 Do KQ, Trabesinger AH, Kirsten-krüger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuénod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo: Glutathione deficit in schizophrenia. European Journal of Neuroscience 2000;12:3721-8. [DOI: 10.1046/j.1460-9568.2000.00229.x] [Cited by in Crossref: 354] [Cited by in F6Publishing: 323] [Article Influence: 17.7] [Reference Citation Analysis]
528 Takahashi N, Sakurai T, Bozdagi-Gunal O, Dorr NP, Moy J, Krug L, Gama-Sosa M, Elder GA, Koch RJ, Walker RH, Hof PR, Davis KL, Buxbaum JD. Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes. Transl Psychiatry 2011;1:e8. [PMID: 22832403 DOI: 10.1038/tp.2011.8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
529 Schlemmer RF, Young JE, Davis JM. Stimulant-induced disruption of non-human primate social behavior and the psychopharmacology of schizophrenia. J Psychopharmacol 1996;10:64-76. [DOI: 10.1177/026988119601000110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
530 Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone Decreases Craving and Relapses in Individuals with Schizophrenia and Cocaine Dependence. Can J Psychiatry 2002;47:671-5. [DOI: 10.1177/070674370204700710] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 3.6] [Reference Citation Analysis]
531 Meyers B, D'Agostino A, Walker J, Kritzer MF. Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats. Neuroscience 2010;165:850-62. [PMID: 19909795 DOI: 10.1016/j.neuroscience.2009.11.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
532 Segal M, Avital A, Rojas M, Hausvater N, Sandbank S, Liba D, Moguillansky L, Tal I, Weizman A. Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes. Psychiatry Research 2004;127:227-35. [DOI: 10.1016/j.psychres.2004.01.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
533 McClure MM, Harvey PD, Goodman M, Triebwasser J, New A, Koenigsberg HW, Sprung LJ, Flory JD, Siever LJ. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology 2010;35:1356-62. [PMID: 20130535 DOI: 10.1038/npp.2010.5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
534 Laruelle M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol. 2014;14:97-102. [PMID: 24524997 DOI: 10.1016/j.coph.2014.01.001] [Cited by in Crossref: 105] [Cited by in F6Publishing: 77] [Article Influence: 15.0] [Reference Citation Analysis]
535 Fausto R, Ribeiro MJS, de Lima JJ. A molecular orbital study on the conformational properties of dopamine [1,2-benzenediol-4(2-aminoethyl)]and dopamine cation. Journal of Molecular Structure 1999;484:181-96. [DOI: 10.1016/s0022-2860(98)00904-1] [Cited by in Crossref: 16] [Article Influence: 0.7] [Reference Citation Analysis]
536 Campion D, d'Amato T, Bastard C, Laurent C, Guedj F, Jay M, Dollfus S, Thibaut F, Petit M, Gorwood P, Babron MC, Waksman G, Martinez M, Mallet J. Genetic study of dopamine D1, D2, and D4 receptors in schizophrenia. Psychiatry Research 1994;51:215-30. [DOI: 10.1016/0165-1781(94)90010-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 1.6] [Reference Citation Analysis]
537 Colzato LS, van den Wildenberg WP, van Wouwe NC, Pannebakker MM, Hommel B. Dopamine and inhibitory action control: evidence from spontaneous eye blink rates. Exp Brain Res 2009;196:467-74. [PMID: 19484465 DOI: 10.1007/s00221-009-1862-x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
538 Godar SC, Bortolato M. Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission. Front Behav Neurosci 2014;8:71. [PMID: 24639636 DOI: 10.3389/fnbeh.2014.00071] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.9] [Reference Citation Analysis]
539 Issy AC, Dos-Santos-Pereira M, Pedrazzi JFC, Kubrusly RCC, Del-Bel E. The role of striatum and prefrontal cortex in the prevention of amphetamine-induced schizophrenia-like effects mediated by nitric oxide compounds. Prog Neuropsychopharmacol Biol Psychiatry 2018;86:353-62. [PMID: 29555252 DOI: 10.1016/j.pnpbp.2018.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
540 Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 2007;94:332-41. [PMID: 17596915 DOI: 10.1016/j.schres.2007.03.033] [Cited by in Crossref: 62] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
541 Hanzawa R, Ohnuma T, Nagai Y, Shibata N, Maeshima H, Baba H, Hatano T, Takebayashi Y, Hotta Y, Kitazawa M, Arai H. No association between glutathione-synthesis-related genes and Japanese schizophrenia. Psychiatry Clin Neurosci 2011;65:39-46. [PMID: 21105962 DOI: 10.1111/j.1440-1819.2010.02157.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
542 Hui L, Zhang X, Yu YQ, Han M, Huang XF, Chen DC, Wang ZR, Du WL, Kou CG, Yu Q, Kosten TR, Zhang XY. Association between DBH 19bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients. Schizophrenia Research 2013;147:236-40. [DOI: 10.1016/j.schres.2013.04.035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
543 Spitzer M. A neurocomputational approach to delusions. Compr Psychiatry 1995;36:83-105. [PMID: 7758303 DOI: 10.1016/s0010-440x(95)90103-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
544 Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci 2017;18:727-40. [DOI: 10.1038/nrn.2017.125] [Cited by in Crossref: 194] [Cited by in F6Publishing: 135] [Article Influence: 48.5] [Reference Citation Analysis]
545 Markianos M, Hatzimanolis J, Lykouras L. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone. Psychiatry Research 1999;89:115-22. [DOI: 10.1016/s0165-1781(99)00098-0] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
546 Large CH. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 2007;21:283-301. [DOI: 10.1177/0269881107077712] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
547 Fujita M, Verhoeff NL, Varrone A, Zoghbi SS, Baldwin RM, Jatlow PA, Anderson GM, Seibyl JP, Innis RB. Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans. European Journal of Pharmacology 2000;387:179-88. [DOI: 10.1016/s0014-2999(99)00817-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
548 Ward RD, Simpson EH, Kandel ER, Balsam PD. Modeling motivational deficits in mouse models of schizophrenia: behavior analysis as a guide for neuroscience. Behav Processes 2011;87:149-56. [PMID: 21338658 DOI: 10.1016/j.beproc.2011.02.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
549 Lidow M, Williams G, Goldman-rakic P. The cerebral cortex: a case for a common site of action of antipsychotics. Trends in Pharmacological Sciences 1998;19:136-40. [DOI: 10.1016/s0165-6147(98)01186-9] [Cited by in Crossref: 124] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
550 Kirrane RM, Siever LJ. New perspectives on schizotypal personality disorder. Curr Psychiatry Rep 2000;2:62-6. [DOI: 10.1007/s11920-000-0044-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
551 Farah R, Haraty H, Salame Z, Fares Y, Ojcius DM, Said Sadier N. Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed J 2018;41:63-87. [PMID: 29866603 DOI: 10.1016/j.bj.2018.03.004] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 19.3] [Reference Citation Analysis]
552 Averbeck BB, Lehman J, Jacobson M, Haber SN. Estimates of projection overlap and zones of convergence within frontal-striatal circuits. J Neurosci 2014;34:9497-505. [PMID: 25031393 DOI: 10.1523/JNEUROSCI.5806-12.2014] [Cited by in Crossref: 95] [Cited by in F6Publishing: 47] [Article Influence: 13.6] [Reference Citation Analysis]
553 Mallya AP, Wang HD, Lee HNR, Deutch AY. Microglial Pruning of Synapses in the Prefrontal Cortex During Adolescence. Cereb Cortex 2019;29:1634-43. [PMID: 29668872 DOI: 10.1093/cercor/bhy061] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 31.0] [Reference Citation Analysis]
554 Mueller TM, Meador-Woodruff JH. Post-translational protein modifications in schizophrenia. NPJ Schizophr 2020;6:5. [PMID: 32123175 DOI: 10.1038/s41537-020-0093-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
555 Jentsch J, D. Verrico C, Le D, Roth RH. Repeated exposure to Δ9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neuroscience Letters 1998;246:169-72. [DOI: 10.1016/s0304-3940(98)00254-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
556 Kesby JP, Cui X, Burne TH, Eyles DW. Altered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia. Front Cell Neurosci 2013;7:111. [PMID: 23882183 DOI: 10.3389/fncel.2013.00111] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
557 Gao M, Liu C, Yang S, Zhen X, Jin G. l-Stepholidine increases the frequency of sEPSC via the activation of D 1 dopamine signaling pathway in rat prelimbic cortical neurons. Acta Pharmacologica Sinica 2007;28:627-33. [DOI: 10.1111/j.1745-7254.2007.00547.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
558 Tyszkiewicz JP, Gu Z, Wang X, Cai X, Yan Z. Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex. J Physiol 2004;554:765-77. [PMID: 14645456 DOI: 10.1113/jphysiol.2003.056812] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 2.7] [Reference Citation Analysis]
559 D'Ambrosio E, Dahoun T, Pardiñas AF, Veronese M, Bloomfield MAP, Jauhar S, Bonoldi I, Rogdaki M, Froudist-Walsh S, Walters JTR, Howes OD. The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study. Psychiatry Res Neuroimaging 2019;291:34-41. [PMID: 31386983 DOI: 10.1016/j.pscychresns.2019.07.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
560 Van Ammers EC, Sellman JD, Mulder RT. Temperament and substance abuse in schizophrenia: is there a relationship? J Nerv Ment Dis. 1997;185:283-288. [PMID: 9171804 DOI: 10.1097/00005053-199705000-00001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 2.4] [Reference Citation Analysis]
561 Soder HE, Cooper JA, Lopez-Gamundi P, Hoots JK, Nunez C, Lawlor VM, Lane SD, Treadway MT, Wardle MC. Dose-response effects of d-amphetamine on effort-based decision-making and reinforcement learning. Neuropsychopharmacology 2021;46:1078-85. [PMID: 32722661 DOI: 10.1038/s41386-020-0779-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
562 Bondy B, de Jonge S, Pander S, Primbs J, Ackenheil M. Identification of dopamine D4 receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction. J Neuroimmunol 1996;71:139-44. [PMID: 8982113 DOI: 10.1016/s0165-5728(96)00148-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
563 Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000;48:381-8. [PMID: 10978721 DOI: 10.1016/s0006-3223(00)00918-5] [Cited by in Crossref: 145] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
564 Park S, Lee J, Folley B, Kim J. Schizophrenia: Putting context in context. Behav Brain Sci 2003;26:98-9. [DOI: 10.1017/s0140525x03380021] [Cited by in Crossref: 12] [Article Influence: 0.7] [Reference Citation Analysis]
565 Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA, Evins AE. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology (Berl) 2012;219:25-34. [PMID: 21695488 DOI: 10.1007/s00213-011-2373-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
566 Craddock N, Owen MJ, O'Donovan MC. The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol Psychiatry. 2006;11:446-458. [PMID: 16505837 DOI: 10.1038/sj.mp.4001808] [Cited by in Crossref: 142] [Cited by in F6Publishing: 117] [Article Influence: 9.5] [Reference Citation Analysis]
567 Marini S, De Berardis D, Vellante F, Santacroce R, Orsolini L, Valchera A, Girinelli G, Carano A, Fornaro M, Gambi F, Martinotti G, Di Giannantonio M. Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Mediators Inflamm 2016;2016:3476240. [PMID: 27524864 DOI: 10.1155/2016/3476240] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
568 Desai A, Benner L, Wu R, Gertsik L, Uz T, Marek GJ, Zhu T. Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. Clin Pharmacokinet 2021;60:79-88. [PMID: 32533536 DOI: 10.1007/s40262-020-00911-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
569 Chermahini SA, Hommel B. The (b)link between creativity and dopamine: spontaneous eye blink rates predict and dissociate divergent and convergent thinking. Cognition 2010;115:458-65. [PMID: 20334856 DOI: 10.1016/j.cognition.2010.03.007] [Cited by in Crossref: 178] [Cited by in F6Publishing: 93] [Article Influence: 16.2] [Reference Citation Analysis]
570 Forster L, Grätz L, Mönnich D, Bernhardt G, Pockes S. A Split Luciferase Complementation Assay for the Quantification of β-Arrestin2 Recruitment to Dopamine D2-Like Receptors. Int J Mol Sci 2020;21:E6103. [PMID: 32847148 DOI: 10.3390/ijms21176103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
571 Kolomeets NS, Uranova NA. Synaptic contacts in schizophrenia: studies using immunocytochemical identification of dopaminergic neurons. Neurosci Behav Physiol 1999;29:217-21. [PMID: 10432512 DOI: 10.1007/BF02465329] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
572 Cannon M, Jones P. Schizophrenia. J Neurol Neurosurg Psychiatry 1996;60:604-13. [PMID: 8648325 DOI: 10.1136/jnnp.60.6.604] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 2.8] [Reference Citation Analysis]
573 Gold JM, Waltz JA, Matveeva TM, Kasanova Z, Strauss GP, Herbener ES, Collins AG, Frank MJ. Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence. Arch Gen Psychiatry 2012;69:129-38. [PMID: 22310503 DOI: 10.1001/archgenpsychiatry.2011.1269] [Cited by in Crossref: 189] [Cited by in F6Publishing: 161] [Article Influence: 21.0] [Reference Citation Analysis]
574 Preti A, Wilson DR. Schizophrenia, cancer and obstetric complications in an evolutionary perspective-an empirically based hypothesis. Psychiatry Investig 2011;8:77-88. [PMID: 21852982 DOI: 10.4306/pi.2011.8.2.77] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
575 Fountoulakis KN, Moeller H, Kasper S, Tamminga C, Yamawaki S, Kahn R, Tandon R, Correll CU, Javed A. The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectr . [DOI: 10.1017/s1092852920001546] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
576 Swerdlow NR, Braff DL, Bakshi VP, Geyer MA. An Animal Model of Sensorimotor Gating Deficits in Schizophrenia Predicts Antipsychotic Drug Action. In: Csernansky JG, editor. Antipsychotics. Berlin: Springer Berlin Heidelberg; 1996. pp. 289-312. [DOI: 10.1007/978-3-642-61007-3_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
577 Williams MR, Galvin K, O'Sullivan B, MacDonald CD, Ching EW, Turkheimer F, Howes OD, Pearce RK, Hirsch SR, Maier M. Neuropathological changes in the substantia nigra in schizophrenia but not depression. Eur Arch Psychiatry Clin Neurosci 2014;264:285-96. [PMID: 24374935 DOI: 10.1007/s00406-013-0479-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
578 Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, Khatri V, Shiota C, Kennedy JP, Lindsley CW, Daws LC, Polley DB, Veenstra-Vanderweele J, Stanwood GD, Magnuson MA, Niswender KD, Galli A. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. PLoS Biol 2010;8:e1000393. [PMID: 20543991 DOI: 10.1371/journal.pbio.1000393] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
579 Nawa H, Takahashi M, Patterson PH. Cytokine and growth factor involvement in schizophrenia—support for the developmental model. Mol Psychiatry 2000;5:594-603. [DOI: 10.1038/sj.mp.4000730] [Cited by in Crossref: 149] [Cited by in F6Publishing: 132] [Article Influence: 7.1] [Reference Citation Analysis]
580 Olney JJ, Warlow SM, Naffziger EE, Berridge KC. Current perspectives on incentive salience and applications to clinical disorders. Curr Opin Behav Sci 2018;22:59-69. [PMID: 29503841 DOI: 10.1016/j.cobeha.2018.01.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 12.3] [Reference Citation Analysis]
581 Weinberger DR, Lipska BK. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophrenia Research 1995;16:87-110. [DOI: 10.1016/0920-9964(95)00013-c] [Cited by in Crossref: 328] [Cited by in F6Publishing: 57] [Article Influence: 12.6] [Reference Citation Analysis]
582 Qiu M, Qu W, Xu X, Yan M, Urade Y, Huang Z. D1/D2 receptor-targeting L-stepholidine, an active ingredient of the Chinese herb Stephonia, induces non-rapid eye movement sleep in mice. Pharmacology Biochemistry and Behavior 2009;94:16-23. [DOI: 10.1016/j.pbb.2009.06.018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
583 Behan AT, Hryniewiecka M, O'Tuathaigh CM, Kinsella A, Cannon M, Karayiorgou M, Gogos JA, Waddington JL, Cotter DR. Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 2012;37:1773-83. [PMID: 22434221 DOI: 10.1038/npp.2012.24] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
584 Hernaus D, Collip D, Lataster J, Ceccarini J, Kenis G, Booij L, Pruessner J, Van Laere K, van Winkel R, van Os J, Myin-Germeys I. COMT Val158Met genotype selectively alters prefrontal [18F]fallypride displacement and subjective feelings of stress in response to a psychosocial stress challenge. PLoS One 2013;8:e65662. [PMID: 23799032 DOI: 10.1371/journal.pone.0065662] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
585 Eyles D, Feldon J, Meyer U. Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. Transl Psychiatry 2012;2:e81. [PMID: 22832818 DOI: 10.1038/tp.2012.6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
586 Yang K, Jin G, Wu J. The neuropharmacology of (-)-stepholidine and its potential applications. Curr Neuropharmacol 2007;5:289-94. [PMID: 19305745 DOI: 10.2174/157015907782793649] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
587 Jentsch J, Roth RH, Taylor JR. Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action. Cognition, emotion and autonomic responses: The integrative role of the prefrontal cortex and limbic structures. Elsevier; 2000. pp. 433-53. [DOI: 10.1016/s0079-6123(00)26028-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
588 Taiminen TJ, Salokangas RK, Saarijärvi S, Niemi H, Lehto H, Ahola V, Syvälahti E. Smoking and cognitive deficits in schizophrenia: a pilot study. Addictive Behaviors 1998;23:263-6. [DOI: 10.1016/s0306-4603(97)00028-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
589 Xiao J, Kannan G, Jones-brando L, Brannock C, Krasnova I, Cadet J, Pletnikov M, Yolken R. Sex-specific changes in gene expression and behavior induced by chronic Toxoplasma infection in mice. Neuroscience 2012;206:39-48. [DOI: 10.1016/j.neuroscience.2011.12.051] [Cited by in Crossref: 73] [Cited by in F6Publishing: 48] [Article Influence: 8.1] [Reference Citation Analysis]
590 Ira E, De Santi K, Lasalvia A, Bonetto C, Zanatta G, Cristofalo D, Bertani M, Bissoli SS, Riolo R, Gardellin F, Morandin I, Ramon L, Tansella M, Ruggeri M, Tosato S; PICOS-Veneto Group. Positive symptoms in first-episode psychosis patients experiencing low maternal care and stressful life events: a pilot study to explore the role of the COMT gene. Stress 2014;17:410-5. [PMID: 25068285 DOI: 10.3109/10253890.2014.948841] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
591 Landek-Salgado MA, Faust TE, Sawa A. Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry 2016;21:10-28. [PMID: 26390828 DOI: 10.1038/mp.2015.141] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
592 Lewis MA, Hunihan L, Watson J, Gentles RG, Hu S, Huang Y, Bronson J, Macor JE, Beno BR, Ferrante M, Hendricson A, Knox RJ, Molski TF, Kong Y, Cvijic ME, Rockwell KL, Weed MR, Cacace AM, Westphal RS, Alt A, Brown JM. Discovery of D1 Dopamine Receptor Positive Allosteric Modulators: Characterization of Pharmacology and Identification of Residues that Regulate Species Selectivity. J Pharmacol Exp Ther 2015;354:340-9. [PMID: 26109678 DOI: 10.1124/jpet.115.224071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
593 Tejedor-real P, Sahagún M, Biguet NF, Mallet J. Neonatal Handling Prevents the Effects of Phencyclidine in an Animal Model of Negative Symptoms of Schizophrenia. Biological Psychiatry 2007;61:865-72. [DOI: 10.1016/j.biopsych.2006.08.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
594 Shontz EC, Souders CL, Schmidt JT, Martyniuk CJ. Domperidone upregulates dopamine receptor expression and stimulates locomotor activity in larval zebrafish ( Danio rerio ). Genes, Brain and Behavior 2018;17:e12460. [DOI: 10.1111/gbb.12460] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
595 Joyce JN, Goldsmith S, Gurevich EV. Limbic circuits and monoamine receptors: Dissecting the effects of antipsy chotics from disease processes. Journal of Psychiatric Research 1997;31:197-217. [DOI: 10.1016/s0022-3956(96)00043-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
596 Ribeyre JM, Lesieur P, Varoquaux O, Dollfus S, Pays M, Petit M. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 1994;36:230-6. [PMID: 7986887 DOI: 10.1016/0006-3223(94)90604-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]
597 Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 2009;65:1024-31. [PMID: 19251247 DOI: 10.1016/j.biopsych.2008.12.029] [Cited by in Crossref: 99] [Cited by in F6Publishing: 82] [Article Influence: 8.3] [Reference Citation Analysis]
598 Leung S, Croft RJ, Baldeweg T, Nathan PJ. Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects. Psychopharmacology (Berl) 2007;194:443-51. [PMID: 17611739 DOI: 10.1007/s00213-007-0865-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
599 Zheng Z, Qiu H, Zheng M, Weng S, Huang Z, Xian R, Lin X. Selective electrochemical determination of dopamine in serum in the presence of ascorbic acid and uric acid by using a CuO nanoleaf electrode. Anal Methods 2014;6:7923-7. [DOI: 10.1039/c4ay01366b] [Cited by in Crossref: 17] [Article Influence: 2.4] [Reference Citation Analysis]
600 Falkai P, Schmitt A, Cannon TD. Pathophysiology of Schizophrenia. In: Gaebel W, editor. Schizophrenia. Chichester: John Wiley & Sons, Ltd; 2011. pp. 31-65. [DOI: 10.1002/9780470978672.ch2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
601 de Leeuw M, Kahn RS, Zandbelt BB, Widschwendter CG, Vink M. Working Memory and Default Mode Network abnormalities in unaffected siblings of schizophrenia patients. Schizophrenia Research 2013;150:555-62. [DOI: 10.1016/j.schres.2013.08.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
602 Ma X, Li C, Meng H, Du L, Wang Q, Wang Y, Deng W, Liu X, Hu X, Murray RM, Collier DA, Li T. Premorbid tobacco smoking is associated with later age at onset in schizophrenia. Psychiatry Res 2010;178:461-6. [PMID: 20493556 DOI: 10.1016/j.psychres.2009.08.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
603 Leung S, Croft RJ, Guille V, Scholes K, O’neill BV, Phan KL, Nathan PJ. Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants. Psychopharmacology 2010;208:233-44. [DOI: 10.1007/s00213-009-1723-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
604 Schreiber R, Newman-tancredi A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT1A receptor activation. Neurobiology of Learning and Memory 2014;110:72-80. [DOI: 10.1016/j.nlm.2013.12.015] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
605 Oranje B, van Oel CJ, Gispen-de Wied CC, Verbaten MN, Kahn RS. Effects of Typical and Atypical Antipsychotics on the Prepulse Inhibition of the Startle Reflex in Patients With Schizophrenia: . Journal of Clinical Psychopharmacology 2002;22:359-65. [DOI: 10.1097/00004714-200208000-00005] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 4.5] [Reference Citation Analysis]
606 Daenen E, Van der Heyden J, Kruse C, Wolterink G, Van Ree J. Adaptation and habituation to an open field and responses to various stressful events in animals with neonatal lesions in the amygdala or ventral hippocampus. Brain Research 2001;918:153-65. [DOI: 10.1016/s0006-8993(01)02987-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
607 Michels L, Scherpiet S, Stämpfli P, Herwig U, Brühl AB. Baseline Perfusion Alterations Due to Acute Application of Quetiapine and Pramipexole in Healthy Adults. Int J Neuropsychopharmacol 2016;19:pyw067. [PMID: 27466220 DOI: 10.1093/ijnp/pyw067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
608 Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci. 2003;1003:138-158. [PMID: 14684442 DOI: 10.1196/annals.1300.063] [Cited by in Crossref: 302] [Cited by in F6Publishing: 267] [Article Influence: 17.8] [Reference Citation Analysis]
609 Bannai M, Kawai N, Nagao K, Nakano S, Matsuzawa D, Shimizu E. Oral administration of glycine increases extracellular serotonin but not dopamine in the prefrontal cortex of rats. Psychiatry Clin Neurosci 2011;65:142-9. [PMID: 21414089 DOI: 10.1111/j.1440-1819.2010.02181.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
610 Goldstein LE, Rasmusson AM, Bunney BS, Roth RH. Role of the amygdala in the coordination of behavioral, neuroendocrine, and prefrontal cortical monoamine responses to psychological stress in the rat. J Neurosci 1996;16:4787-98. [PMID: 8764665 [PMID: 8764665 DOI: 10.1523/jneurosci.16-15-04787.1996] [Cited by in Crossref: 242] [Article Influence: 9.7] [Reference Citation Analysis]
611 Rojas Cabrera JM, Price JB, Rusheen AE, Goyal A, Jondal D, Barath AS, Shin H, Chang SY, Bennet KE, Blaha CD, Lee KH, Oh Y. Advances in neurochemical measurements: A review of biomarkers and devices for the development of closed-loop deep brain stimulation systems. Rev Anal Chem 2020;39:188-99. [PMID: 33883813 DOI: 10.1515/revac-2020-0117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
612 Bourgeois JA, Maddock RJ, Rogers L, Greco CM, Mangrulkar RS, Saint S. Neurosarcoidosis and Delirium. Psychosomatics 2005;46:148-50. [DOI: 10.1176/appi.psy.46.2.148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
613 Jha O, Yadav T, Yadav R. Structural and vibrational study of a neurotransmitter molecule: Dopamine [4-(2-aminoethyl) benzene-1,2-diol]. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2018;189:473-84. [DOI: 10.1016/j.saa.2017.07.067] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
614 Huang SY, Chen LH, Wang MF, Hsu CC, Chan CH, Li JX, Huang HY. Lactobacillus paracasei PS23 Delays Progression of Age-Related Cognitive Decline in Senescence Accelerated Mouse Prone 8 (SAMP8) Mice. Nutrients 2018;10:E894. [PMID: 30002347 DOI: 10.3390/nu10070894] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
615 Hernaus D, Collip D, Kasanova Z, Winz O, Heinzel A, van Amelsvoort T, Shali SM, Booij J, Rong Y, Piel M, Pruessner J, Mottaghy FM, Myin-Germeys I. No evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder. Transl Psychiatry 2015;5:e547. [PMID: 25871972 DOI: 10.1038/tp.2015.37] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
616 Arguello PA, Gogos JA. Modeling Madness in Mice: One Piece at a Time. Neuron 2006;52:179-96. [DOI: 10.1016/j.neuron.2006.09.023] [Cited by in Crossref: 218] [Cited by in F6Publishing: 201] [Article Influence: 14.5] [Reference Citation Analysis]
617 Koreki A, Maeda T, Okimura T, Terasawa Y, Kikuchi T, Umeda S, Nishikata S, Yagihashi T, Kasahara M, Nagai C, Moriyama Y, Den R, Watanabe T, Kikumoto H, Kato M, Mimura M. Dysconnectivity of the Agency Network in Schizophrenia: A Functional Magnetic Resonance Imaging Study. Front Psychiatry 2019;10:171. [PMID: 31001152 DOI: 10.3389/fpsyt.2019.00171] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
618 Lingjærde O. New perspectives on biological treatment of schizophrenia. Acta Psychiatr Scand 1994;90:102-7. [DOI: 10.1111/j.1600-0447.1994.tb05898.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
619 Bonoldi I, Howes OD. Presynaptic dopaminergic function: implications for understanding treatment response in psychosis. CNS Drugs 2014;28:649-63. [PMID: 24919790 DOI: 10.1007/s40263-014-0177-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
620 Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008;34:354-66. [PMID: 18283048 DOI: 10.1093/schbul/sbm168] [Cited by in Crossref: 238] [Cited by in F6Publishing: 207] [Article Influence: 18.3] [Reference Citation Analysis]
621 Chong VZ, Costain W, Marriott J, Sindwani S, Knauer DJ, Wang J, Young LT, Maccrimmon D, Mishra RK. Differential display polymerase chain reaction reveals increased expression of striatal rat glia-derived nexin following chronic clozapine treatment. Pharmacogenomics J 2004;4:379-87. [DOI: 10.1038/sj.tpj.6500274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
622 Mokrani M, Duval F, Crocq M, Bailey P, Macher J. Multihormonal responses to apomorphine in mental illness. Psychoneuroendocrinology 1995;20:365-75. [DOI: 10.1016/0306-4530(94)00065-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
623 Katsel P, Roussos P, Pletnikov M, Haroutunian V. Microvascular anomaly conditions in psychiatric disease. Schizophrenia - angiogenesis connection. Neurosci Biobehav Rev 2017;77:327-39. [PMID: 28396239 DOI: 10.1016/j.neubiorev.2017.04.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
624 Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 2001;98:4746-51. [PMID: 11296301 DOI: 10.1073/pnas.081071198] [Cited by in Crossref: 850] [Cited by in F6Publishing: 786] [Article Influence: 42.5] [Reference Citation Analysis]
625 Kwon S, Kim D, Park H, Yoo D, Park HJ, Hahm DH, Lee H, Kim ST. Prefrontal-limbic change in dopamine turnover by acupuncture in maternally separated rat pups. Neurochem Res 2012;37:2092-8. [PMID: 22714092 DOI: 10.1007/s11064-012-0830-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
626 Walker EF, Neumann CC, Baum K, Davis DM, Diforio D, Bergman A. The developmental pathways to schizophrenia: Potential moderating effects of stress. Dev Psychopathol 1996;8:647-65. [DOI: 10.1017/s0954579400007343] [Cited by in Crossref: 24] [Article Influence: 2.0] [Reference Citation Analysis]
627 Erhardt S, Schwieler L, Imbeault S, Engberg G. The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology 2017;112:297-306. [DOI: 10.1016/j.neuropharm.2016.05.020] [Cited by in Crossref: 110] [Cited by in F6Publishing: 94] [Article Influence: 27.5] [Reference Citation Analysis]
628 Martini A, Cordella A, Pisani A, Mercuri NB, Guatteo E. Neurotensin receptors inhibit mGluR I responses in nigral dopaminergic neurons via a process that undergoes functional desensitization by G-protein coupled receptor kinases. Neuropharmacology 2019;155:76-88. [PMID: 31128122 DOI: 10.1016/j.neuropharm.2019.05.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
629 Rabin RA, Zakzanis KK, Daskalakis ZJ, George TP. Effects of cannabis use status on cognitive function, in males with schizophrenia. Psychiatry Res 2013;206:158-65. [PMID: 23246245 DOI: 10.1016/j.psychres.2012.11.019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
630 Goff DC, Heckers S, Freudenreich O. SCHIZOPHRENIA. Medical Clinics of North America 2001;85:663-89. [DOI: 10.1016/s0025-7125(05)70335-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
631 Rammsayer TH. NMDA Receptor Activity and the Transmission of Sensory Input into Motor Output in Introverts and Extraverts. The Quarterly Journal of Experimental Psychology Section B 2003;56:207-21. [DOI: 10.1080/02724990244000098] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
632 Sendt KV, Giaroli G, Tracy DK. Beyond dopamine: glutamate as a target for future antipsychotics. ISRN Pharmacol 2012;2012:427267. [PMID: 22830044 DOI: 10.5402/2012/427267] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
633 McKinzie DL, Bymaster FP. Muscarinic mechanisms in psychotic disorders. Handb Exp Pharmacol 2012;:233-65. [PMID: 23027418 DOI: 10.1007/978-3-642-25758-2_9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
634 Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009;15:2550-9. [PMID: 19689327 DOI: 10.2174/138161209788957528] [Cited by in Crossref: 157] [Cited by in F6Publishing: 128] [Article Influence: 13.1] [Reference Citation Analysis]
635 Yuen O, Caligiuri MP, Williams R, Dickson RA. Tardive Dyskinesia and Positive and Negative Symptoms of Schizophrenia: A Study Using Instrumental Measures. Br J Psychiatry 1996;168:702-8. [DOI: 10.1192/bjp.168.6.702] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
636 Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, McGuire P. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 2011;168:1311-7. [PMID: 21768612 DOI: 10.1176/appi.ajp.2011.11010160] [Cited by in Crossref: 223] [Cited by in F6Publishing: 181] [Article Influence: 22.3] [Reference Citation Analysis]
637 Lidow MS, Goldman-Rakic PS. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci U S A 1994;91:4353-6. [PMID: 8183912 DOI: 10.1073/pnas.91.10.4353] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 4.0] [Reference Citation Analysis]
638 O'daly OG, Guillin O, Tsapakis E, Martinez D, Shergill SS, Murray RM, Buckley PF. Schizophrenia and Substance Abuse Co-Morbidity: A Role for Dopamine Sensitization? Journal of Dual Diagnosis 2005;1:11-40. [DOI: 10.1300/j374v01n02_03] [Cited by in Crossref: 12] [Article Influence: 0.8] [Reference Citation Analysis]
639 Lech MA, Leśkiewicz M, Kamińska K, Rogóż Z, Lorenc-Koci E. Glutathione Deficiency during Early Postnatal Development Causes Schizophrenia-Like Symptoms and a Reduction in BDNF Levels in the Cortex and Hippocampus of Adult Sprague-Dawley Rats. Int J Mol Sci 2021;22:6171. [PMID: 34201038 DOI: 10.3390/ijms22126171] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
640 Mitterauer B. Nonfunctional Glial Proteins in Tripartite Synapses: A Pathophysiological Model of Schizophrenia. Neuroscientist 2005;11:192-8. [DOI: 10.1177/1073858404265745] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
641 Chen da C, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, Li YL, Wang N, Yang KB, Xiu MH. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl). 2009;207:375-380. [PMID: 19787338 DOI: 10.1007/s00213-009-1665-6] [Cited by in Crossref: 95] [Cited by in F6Publishing: 95] [Article Influence: 7.9] [Reference Citation Analysis]
642 Chartoff EH, Heusner CL, Palmiter RD. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 2005;30:1324-33. [PMID: 15688082 DOI: 10.1038/sj.npp.1300678] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
643 Chen C, Yeh Y, Kuo S, Ho P, Liang C, Yen C, Lu R, Huang S. Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment. Psychoneuroendocrinology 2016;65:67-75. [DOI: 10.1016/j.psyneuen.2015.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
644 Large CH, Webster EL, Goff DC. The potential role of lamotrigine in schizophrenia. Psychopharmacology 2005;181:415-36. [DOI: 10.1007/s00213-005-0020-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
645 Gothelf D, Soreni N, Nachman RP, Tyano S, Hiss Y, Reiner O, Weizman A. Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia. European Neuropsychopharmacology 2000;10:389-95. [DOI: 10.1016/s0924-977x(00)00097-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
646 Sclan SG, Saillon A, Franssen E, Hugonot-diener L, Saillon A, Reisberg B. THE BEHAVIOR PATHOLOGY IN ALZHEIMER'S DISEASE RATING SCALE (BEHAVE-AD): RELIABILITY AND ANALYSIS OF SYMPTOM CATEGORY SCORES. Int J Geriat Psychiatry 1996;11:819-30. [DOI: 10.1002/(sici)1099-1166(199609)11:9<819::aid-gps389>3.0.co;2-s] [Cited by in Crossref: 56] [Article Influence: 2.2] [Reference Citation Analysis]
647 Totah NK, Kim YB, Homayoun H, Moghaddam B. Anterior cingulate neurons represent errors and preparatory attention within the same behavioral sequence. J Neurosci 2009;29:6418-26. [PMID: 19458213 DOI: 10.1523/JNEUROSCI.1142-09.2009] [Cited by in Crossref: 79] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
648 Mackowick KM, Heishman SJ, Wehring HJ, Liu F, McMahon RP, Kelly DL. Illicit drug use in heavy smokers with and without schizophrenia. Schizophr Res 2012;139:194-200. [PMID: 22591779 DOI: 10.1016/j.schres.2012.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
649 Reichenberg A. Cognitive impairment as a risk factor for psychosis. Dialogues Clin Neurosci 2005;7:31-8. [PMID: 16060594 [PMID: 16060594 DOI: 10.31887/dcns.2005.7.1/areichenberg] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
650 Hui L, Zhang X, Huang XF, Han M, Fernandez F, Yu Y, Sun S, Li W, Chen DC, Xiu MH, Kosten TR, Zhang XY. The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia. Journal of Psychiatric Research 2012;46:733-7. [DOI: 10.1016/j.jpsychires.2012.02.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
651 Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work-from receptors to reality. NeuroRx 2006;3:10-21. [PMID: 16490410 DOI: 10.1016/j.nurx.2005.12.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
652 Stockton ME, Rasmussen K. Olanzapine, a novel atypical antipsychotic, reversesd-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology 1996;124:50-6. [DOI: 10.1007/bf02245605] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
653 du Bois TM, Hsu CW, Li Y, Tan YY, Deng C, Huang XF. Altered dopamine receptor and dopamine transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor blockade. Neurochem Res 2008;33:1224-31. [PMID: 18256931 DOI: 10.1007/s11064-007-9571-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
654 Nadal R. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist. CNS Drug Rev 2001;7:265-82. [PMID: 11607043 DOI: 10.1111/j.1527-3458.2001.tb00199.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
655 Zheng Y, Huang Z, Zhao C, Weng S, Zheng W, Lin X. A gold electrode with a flower-like gold nanostructure for simultaneous determination of dopamine and ascorbic acid. Microchim Acta 2013;180:537-44. [DOI: 10.1007/s00604-013-0964-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
656 Peterburs J, Nitsch AM, Miltner WH, Straube T. Impaired Representation of Time in Schizophrenia Is Linked to Positive Symptoms and Cognitive Demand. PLoS One 2013;8:e67615. [PMID: 23826328 DOI: 10.1371/journal.pone.0067615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
657 Schnider A, Guggisberg A, Nahum L, Gabriel D, Morand S. Dopaminergic modulation of rapid reality adaptation in thinking. Neuroscience 2010;167:583-7. [PMID: 20219638 DOI: 10.1016/j.neuroscience.2010.02.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
658 Carvalho AL, Duarte CB, Carvalho AP. Regulation of AMPA receptors by phosphorylation. Neurochem Res 2000;25:1245-55. [PMID: 11059799 DOI: 10.1023/a:1007644128886] [Cited by in Crossref: 54] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
659 Krummenacher P, Mohr C, Haker H, Brugger P. Dopamine, Paranormal Belief, and the Detection of Meaningful Stimuli. Journal of Cognitive Neuroscience 2010;22:1670-81. [DOI: 10.1162/jocn.2009.21313] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
660 Spitzer M, Braun U, Hermle L, Maier S. Associative semantic network dysfunction in thought-disordered schizophrenic patients: direct evidence from indirect semantic priming. Biol Psychiatry 1993;34:864-77. [PMID: 8110913 DOI: 10.1016/0006-3223(93)90054-h] [Cited by in Crossref: 200] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
661 Drew AE, Derbez AE, Werling LL. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse 2000;38:10-6. [PMID: 10941136 DOI: 10.1002/1098-2396(200010)38:1<10::AID-SYN2>3.0.CO;2-T] [Cited by in Crossref: 64] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
662 Mohr C, Sándor PS, Landis T, Fathi M, Brugger P. Blinking and schizotypal thinking. J Psychopharmacol 2005;19:513-20. [DOI: 10.1177/0269881105056538] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
663 Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996;93:9235-40. [PMID: 8799184 DOI: 10.1073/pnas.93.17.9235] [Cited by in Crossref: 864] [Cited by in F6Publishing: 750] [Article Influence: 34.6] [Reference Citation Analysis]
664 Kamal Eddin FB, Fen YW. The Principle of Nanomaterials Based Surface Plasmon Resonance Biosensors and Its Potential for Dopamine Detection. Molecules 2020;25:E2769. [PMID: 32549390 DOI: 10.3390/molecules25122769] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
665 Bas A, Gultekin G, Incir S, Bas TO, Emul M, Duran A. Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics. Psychiatry Res 2017;247:84-9. [PMID: 27871032 DOI: 10.1016/j.psychres.2016.11.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
666 Pomilio AB, Vitale AA, Ciprian-Ollivier J, Cetkovich-Bakmas M, Gómez R, Vázquez G. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. J Ethnopharmacol 1999;65:29-51. [PMID: 10350367 DOI: 10.1016/s0378-8741(98)00163-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
667 Robol V, Tibber MS, Anderson EJ, Bobin T, Carlin P, Shergill SS, Dakin SC. Reduced crowding and poor contour detection in schizophrenia are consistent with weak surround inhibition. PLoS One 2013;8:e60951. [PMID: 23585865 DOI: 10.1371/journal.pone.0060951] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
668 Essali A, Ali G. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Syst Rev 2012;:CD004162. [PMID: 22336800 DOI: 10.1002/14651858.CD004162.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
669 Locklear MN, Michaelos M, Collins WF, Kritzer MF. Gonadectomy but not biological sex affects burst-firing in dopamine neurons of the ventral tegmental area and in prefrontal cortical neurons projecting to the ventral tegmentum in adult rats. Eur J Neurosci 2017;45:106-20. [PMID: 27564091 DOI: 10.1111/ejn.13380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
670 Dauvermann MR, Whalley HC, Schmidt A, Lee GL, Romaniuk L, Roberts N, Johnstone EC, Lawrie SM, Moorhead TW. Computational neuropsychiatry - schizophrenia as a cognitive brain network disorder. Front Psychiatry 2014;5:30. [PMID: 24723894 DOI: 10.3389/fpsyt.2014.00030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
671 Zhuo C, Zhu J, Qin W, Qu H, Ma X, Tian H, Xu Q, Yu C. Functional connectivity density alterations in schizophrenia. Front Behav Neurosci 2014;8:404. [PMID: 25477799 DOI: 10.3389/fnbeh.2014.00404] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
672 Broyd A, Balzan RP, Woodward TS, Allen P. Dopamine, cognitive biases and assessment of certainty: A neurocognitive model of delusions. Clin Psychol Rev 2017;54:96-106. [PMID: 28448827 DOI: 10.1016/j.cpr.2017.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
673 Modinos G, Allen P, Grace AA, McGuire P. Translating the MAM model of psychosis to humans. Trends Neurosci 2015;38:129-38. [PMID: 25554679 DOI: 10.1016/j.tins.2014.12.005] [Cited by in Crossref: 91] [Cited by in F6Publishing: 75] [Article Influence: 13.0] [Reference Citation Analysis]
674 Colzato LS, Slagter HA, de Rover M, Hommel B. Dopamine and the Management of Attentional Resources: Genetic Markers of Striatal D2 Dopamine Predict Individual Differences in the Attentional Blink. Journal of Cognitive Neuroscience 2011;23:3576-85. [DOI: 10.1162/jocn_a_00049] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
675 Duval F, Mokrani M, Monreal J, Bailey P, Valdebenito M, Crocq M, Macher J. Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests. Psychoneuroendocrinology 2003;28:627-42. [DOI: 10.1016/s0306-4530(02)00047-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
676 Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci U S A 1999;96:13432-7. [PMID: 10557338 DOI: 10.1073/pnas.96.23.13432] [Cited by in Crossref: 198] [Cited by in F6Publishing: 161] [Article Influence: 9.0] [Reference Citation Analysis]
677 Kessler RM. Dopamine Receptors and Dopamine Release. Imaging of the Human Brain in Health and Disease. Elsevier; 2014. pp. 289-339. [DOI: 10.1016/b978-0-12-418677-4.00012-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
678 Drew AE, Werling LL. Nicotinic receptor-mediated regulation of the dopamine transporter in rat prefrontocortical slices following chronic in vivo administration of nicotine. Schizophrenia Research 2003;65:47-55. [DOI: 10.1016/s0920-9964(02)00500-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
679 Yeap S, Thakore J. Stress axis dysfunction in schizophrenia. Eur psychiatr 2005;20:S307-12. [DOI: 10.1016/s0924-9338(05)80181-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
680 Lieberman JA. Dopamine Partial Agonists: A New Class of Antipsychotic. CNS Drugs 2004;18:251-67. [DOI: 10.2165/00023210-200418040-00005] [Cited by in Crossref: 198] [Cited by in F6Publishing: 143] [Article Influence: 11.6] [Reference Citation Analysis]
681 Javitt DC, Balla A, Sershen H, Lajtha A. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biological Psychiatry 1999;45:668-79. [DOI: 10.1016/s0006-3223(98)00237-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
682 Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Research Reviews 1999;29:250-64. [DOI: 10.1016/s0165-0173(99)00002-8] [Cited by in Crossref: 124] [Cited by in F6Publishing: 15] [Article Influence: 5.6] [Reference Citation Analysis]
683 Etou K, Kuroki T, Kawahara T, Yonezawa Y, Tashiro N, Uchimura H. Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex. Pharmacol Biochem Behav 1998;61:427-34. [PMID: 9802838 DOI: 10.1016/s0091-3057(98)00128-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
684 Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 2007;51:s13-8. [PMID: 18055930 DOI: 10.1192/bjp.191.51.s13] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 6.2] [Reference Citation Analysis]
685 Tsou JY. Intervention, causal reasoning, and the neurobiology of mental disorders: Pharmacological drugs as experimental instruments. Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 2012;43:542-51. [DOI: 10.1016/j.shpsc.2012.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
686 Llorca PM, Pere JJ. [Leponex, 10 years after -- a clinical review]. Encephale 2004;30:474-91. [PMID: 15627052 DOI: 10.1016/s0013-7006(04)95462-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
687 Bennett MR. The prefrontal-limbic network in depression: Modulation by hypothalamus, basal ganglia and midbrain. Prog Neurobiol 2011;93:468-87. [PMID: 21349315 DOI: 10.1016/j.pneurobio.2011.01.006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
688 Spanarello S, Beoni AM, Mina G, Amantini K, Colotto A. Analysis of differential clinical profiles of different antipsychotic molecules in the first psychotic episode: a retrospective study. Encephale 2005;31:692-7. [PMID: 16462688 DOI: 10.1016/s0013-7006(05)82427-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
689 Siever LJ. Biologic factors in schizotypal personal disorders. Acta Psychiatr Scand Suppl 1994;384:45-50. [PMID: 7879643 DOI: 10.1111/j.1600-0447.1994.tb05890.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [